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A number of autoimmune and chronic inflammatory diseases are related to 
environmental stress. Aryl hydrocarbon receptor (AHR) is regarded as an environmental 
sensor integrating immune responses with environmental stress and thereby influencing 
the extent of host immune response. The physiological role of AHR, particularly, in the 
immune response remains a key question after the discovery that AHR can modulate 
Th17/Treg axis in a ligand specific manner. However, discovery of a non-DRE mediated 
AHR activation in addition to its canonical DRE-mediated pathway further adds to this 
complexity thereby necessitating a more critical approach in delineating the role of AHR 
in the context of Th17/Treg balance. Selective AHR modulators (SAHRMs) are a 
recently identified class of compounds that are capable of binding to AHR and repress 
cytokine- driven gene expression without activating DRE-driven responses We have 
used three classes of AHR ligands namely agonist, antagonist and partial antagonist 
(SAHRM) to delineate the role of AHR in the context of Th17/Treg regulation both in 
vitro and in vivo. Here, we show that inhibition of the DRE-driven response is sufficient 
to suppress the Th17 differentiation. Also, we show that the suppression of Treg 
differentiation is dependent on the inhibition of the non-DRE mediated pathway. We 
have also delineated the role of DRE vs non-DRE driven responses of Th17 regulation 
in both an acute vs a chronic Th17 mediated diseases. In an acute inflammation using 
C. rodentium model of IBD (Inflammatory Bowel Disease) AHR agonist enhanced Th17 
production and thereby promoted resolution of infection. On the other hand, using S. 
rectivirgula in a chronic mouse model of Hypersensitivity Pneumonitis we show that 
inhibition of DRE and /or non-DRE mediated response had minimal effect on IL-17A 
production but precludes Th17 plasticity by enabling secretion of alternate lineage anti-
inflammatory cytokines. This work has profound implication in pharmacological 
intervention in autoimmune and chronic inflammatory diseases by developing AHR 
compounds which can modulate DRE and non-DRE driven responses. 
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1.1 Introduction 
The aryl hydrocarbon receptor (AHR) is a highly conserved molecule and its 
functional orthologues are found throughout a number of animal species from 
mammals, amphibians and reptiles to aves suggesting its importance in the animal 
kingdom. Studies on AHR for the past 50 years have revealed its role as a sensor 
for environmental toxin and a mediator of chemical toxicity. Historically, 
immunotoxicity of AHR was deduced from studies of halogenated aromatic 
compounds (HAH) and 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD; ‘‘dioxin’’), the 
most toxic ligand that binds to AHR with high affinity. AHR was originally discovered 
as a transcription factor that mediated cellular toxicity by upregulating xenobiotic 
enzymes through P450 cytochrome (Cyp1A) genes. Studies with mouse Cyp1A1 
gene expression identified enhancer sequences5’-TNGCGTG-3’ on AHR target 
genes referred to as xenobiotic response elements (XRE) or dioxin response 
elements (DRE). AHR has been widely studied in the context of TCDD mediated 
toxicity, which induces liver damage, thymic involution, epithelial hyperplasia and 
immune dysregulation.  AHR is expressed in lung, heart, thymus, liver and placenta 
essential for diverse roles in these organs. Recently, AHR has been shown to play 
a critical role in the homeostasis of the immune system.  
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1.2 Structure of AHR 
AHR belongs to Per-ARNT-Sim (PAS) superfamily of proteins. General domain 
organization of AHR consists of an N-terminal basic helix-loop-helix (bHLH) 
domain, a C-terminal variable domain and a central PAS domain which consists of 
260-310 amino acids and contains two conserved hydrophobic repeats PAS-A and 
PAS-B which mediate a number of diverse functions including binding to AHR 
specific ligand, and heterodimerization with aryl hydrocarbon translocator (ARNT) to 
form the active transcription factor that translocates to the nucleus and interacts 
with other chaperone proteins. The basic helix-loop-helix (bHLH) domain is also 
involved in DNA binding and heterodimerization. The variable C-terminal domain 
contains the transactivation domain (TAD), which mediates transcription after target 
DNA binding (Fig.1). 
 
 
Fig.1. Structure of AHR. Model diagram depicting the domain organization of 
AHR. AHR consists of a highly conserved N-terminal domain containing the bHLH, a 
central hydrophobic region containing the PAS-A and PAS-B domains and a poorly 
conserved C-terminal domain containing the transactivation domain which is required for 
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transcription after target DNA binding. AHR binds to PAH (polycyclic aromatic 
hydrocarbons), HAH (halogenated aromatic hydrocarbons) and also non-aromatic 
compounds by binding to the PAS-B domain. 
 
1.3 Canonical AHR pathway  
AHR is a cytosolic transcription factor belonging to the basic helix-loop-helix 
(bHLH)- Per-ARNT-Sim (PAS) family and is evolutionarily conserved across a 
number of species in animal the kingdom  [1]. In absence of a ligand, AHR remains 
complexed with heat shock protein 90 (hsp90) [2, 3],immunophilin-related protein 
(XAP2) [4, 5] and phosphoprotein p23 [6]. Upon ligand binding AHR undergoes 
conformational changes and exposes the nuclear localization signal (NLS) and 
translocates to the nucleus from the cytosol [7]. In the nucleus it dissociates from 
the cytosolic proteins and dimerizes with ARNT[8] to adopt an active form of 
transcription factor that can bind to the specific DNA sites (xenobiotic response 
elements XRE) with high affinity and modulate transcription of AHR responsive 
genes (Fig2). AHR has been mainly studied as a mediator of dioxin toxicity [9, 10] 
but recent studies have shown that it plays an important role in the development of 
liver [11], vascular system [12] and modulates signaling in immune cells in 
response to environmental toxins. 
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Fig. 2.  The canonical AHR pathway. Model diagram depicting the AHR canonical 
pathway. AHR remains complexed with heat shock protein (hsp90) and p23 in absence of 
ligand binding in the cytosol. Upon ligand binding it heterodimerizes with AHR-nuclear 
translocator (AHRNT) and is transported to the nucleus and initiates transcription of its 
target genes. One of the most potent genes induced by AHR activation is Cyp1A1, a p450 
cytochrome required to detoxify xenobiotics. 
 
1.4 Defects in AHR-null mice 
AHR knockout mice provide a good understanding of the physiological role of AHR. 
AHR deficient mice have been shown to have a myriad of defects in hepatic, 
vascular and hematopoietic development along with a lower life expectancy and 
reduced reproductive capacity. In liver, AHR is required to close the ductus venosus 
after birth and its deficiency causes impaired blood flow in the liver along with portal 
tract fibrosis that result in a significantly smaller liver. AHR deficiency also leads to 
a number of reproductive defects including death of females during pregnancy and 
defects in lactation that may be due the inability to sufficiently synthesize hormones, 
Ligand
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sudden death of pups and smaller litter size. In the immune system AHR deficiency 
leads to decreased lymphocytes in spleen and have reduced ability to maintain 
compartments of hematopoietic stem cells. 
 
1.5 AHR in T cell biology 
 
CD4+ T cells play a central role in adaptive immune response (Fig3). They are 
capable of exerting a myriad of functions which ranges from helping B cells to 
generate antibody and regulating CD8+ T cells responses, to inducing immune 
response to a variety of pathogenic microorganisms, regulating and fine tuning 
autoimmune responses, and establishing immunologic memory. Following their 
initial characterization in 1986 by Mosmann and Coffman into two distinct subsets 
of Th1 and Th2 lineages, a number of distinct CD4+ T cell subsets have emerged. 
Th17 and Treg cells are two such lineages that have well characterized in recent 
times [13, 14]. These subsets are distinguished by their cytokine profile and effector 
function. Th1 cells secrete IFN-γ and lymphotoxin in response to intracellular 
pathogens. Th2 cells produce IL-4, IL-5 and IL-13 to mediate immune response to 
extracellular pathogen. In response to extracellular bacteria and fungi Th17 cells 
secrete pro-inflammatory cytokines like IL-17A, IL17F, IL-21 and also IL-22 [14, 15]. 
Tregs on the other hand secrete anti-inflammatory cytokines and mediators and are 
critical for control of inflammatory and autoimmune responses.  
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Fig. 3. CD4+ T cell subsets and their cytokines. Upon antigenic stimulation a naïve 
CD4+ T cell can give rise to at least 4 different subtypes of T helper cells. In presence of IL-
12 and intracellular pathogens like bacteria it can differentiate to Th1 cells by upregulating 
T-bet and secrete IFN-γ and in presence of IL-4 and extracellular parasites it can 
differentiate to Th2 cells by upregulating GATA3 which can secrete IL-4, IL-5 and IL-13. In 
presence of  TGF-β and IL-6 and extracellular bacteria and fungi a naïve CD4+ T cell 
differentiates to Th17 cells by upregulating RORγt and secrete cytokines like IL-17A, IL-17F 
and IL-22. Tregs are induced peripherally in the presence of above mentioned antigens and 
TGF-β to upregulate Foxp3 and can secrete immunosuppressive cytokines like TGF-β and 
IL-10. AHR is expressed in both Th17 and Treg cells and can promote their differentiation 
in a ligand specific manner. 
 
The IL-17 family of cytokines includes IL-17A, IL-17F, IL-17B, IL-17C, IL-17D and 
IL-17E (IL-25). IL-17A and IL-17F share the highest structural homology (50%) and 
have a number of similar functional properties. The IL-17 receptor family includes 5 
members from IL-17RA to IL-17RE and homodimers or heterodimers of these 
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receptors bind to IL-17 family cytokines [16]. IL-17A homodimers or Il-17A-Il17F 
heterodimers binds to the heterodimer of IL-17RA and IL-17-RC. With the exception 
of IL-17E, all members of the IL17 family of cytokines induce expression of 
proinflammatory cytokines like IL-1β and tumor necrosis factor (TNF) by other cell 
types and also promote neutrophil migration suggesting a common role for these 
cytokines in certain inflammatory diseases [14, 16]. A naïve CD4+T cell 
differentiates into Th17 cells in presence of TGF-β1 and IL-6 or IL-21 by 
upregulating RORγt, a master regulator of Th17 cell differentiation. IL-6 or IL-21 
alone cannot drive the differentiation of Th17 cells in the absence of TGF-β1 which 
is responsible for dampening the Th1 and Th2 responses [17]. However recently, it 
has been shown that this requirement for TGF-β1 can be overcome by IL-1β in the 
presence of either IL-6 or IL-21 [18]. It is becoming increasingly clear that a number 
of inflammatory and autoimmune diseases that were initially thought to be mediated 
by Th1 are actually driven by an over-exuberant Th17 response. Different disease 
models including experimental autoimmune encephalomyelitis (EAE), collagen 
induced arthritis (CIA) and autoimmune myocarditis are directly linked with IL-17A 
cytokine as neutralizing this cytokine with IL-17A specific antibodies can block the 
initiation of the disease [17]. 
Regulatory T cells (Tregs) are another subset of CD4+T cells, which plays an 
important role in the suppression of autoimmune diseases, minimize the deleterious 
effects of pathogen, maintain self-tolerance and control the exacerbation of 
inflammatory processes [19]. Foxp3 expression is a hallmark of CD4+ Tregs. TGF-
β1 along with IL-2 induces the differentiation of Treg from naïve CD4+ T cells. Tregs 
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can suppress inflammatory responses in a number of ways including secretion of 
inhibitory cytokines like TGF-β and IL-10, direct cytolysis through secretion of 
granzymes A/ B, metabolic disruption and by inhibition of dendritic cell activation 
and function [19]  Thus, Tregs play a critical role in immune cell homeostasis and  
TGF-β1 can induce differentiation of both Th17 and Treg cells. In fact, T cell 
activation in the presence of TGF-β1 induces expression of both RORγt and Foxp3. 
Foxp3 suppresses RORγt by directly binding to it during Treg cell differentiation 
while Foxp3 is suppressed under Th17 polarizing conditions [20]. Suppression of 
RORγt by Foxp3 can be overcome by cytokines that signal through Stat3 like IL-6, 
IL-21 and IL-23 [20]. Thus the Th17/Treg balance is carefully controlled by a 
dynamic interplay between cytokines and the downstream transcription factors they 
induce [21].  
In recent times, activation of AHR by its ligand has been shown to influence 
differentiation of different subsets of T helper cells. An orally active anti-allergic 
AHR agonist M50367 has been shown to regulate the Th1/Th2 cell axis. Mice 
treated with this agent in an allergic experimental model had decreased response 
via suppression of IgE and peritoneal eosinophilia resulting in reduced airway 
hyperresponsiveness. M50367 skews naïve CD4+ T cells to a Th1 phenotype, 
which is mediated by the suppression of Th2 master transcription factor GATA3, 
leading to a decreased allergic activity. These results suggest that AHR is an 
attractive therapeutic target for the treatment of allergic diseases. 
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The most potent ligand of AHR, TCDD has profound effects on both humoral and 
cellular immunity. TCDD is unaffected by the metabolizing enzymes induced by 
AHR activation and its persistence in the cellular milieu is the primary reason for its 
potent toxicity [22]. TCDD exposure causes thymic atrophy by targeting the 
intrathymic progenitor cells [23],acute thymocyte cell loss and proliferation arrest 
[24] and preferential thymic egress of DN thymocytes in the periphery [25]. 
Recently, two groups have reported a dichotomous behavior of AHR agonists. 
Quintana et al showed that activation of AHR by TCDD led to the induction of 
functional Treg cells that suppressed experimental autoimmune encephalomyelitis 
or EAE in a TGF-β1-dependent mechanism. In line with this, Kimura et al using 
AHR deficient animals showed that AHR signaling can promote the differentiation of 
Treg cells. But another group recently showed that, activation of AHR by 6-
formylindolo[3,2-b]carbazole (FICZ), another agonist ligand of AHR, results in the 
induction of TH17 differentiation leading to the worsening of EAE disease pathology 
(Fig. 4). 
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Fig. 4.  AHR regulates Th17/Treg axis in a ligand specific manner. AHR binds to 
TCDD, an agonist, and promotes Treg differentiation thereby protecting mice from EAE 
whereas treatment with FICZ, also an agonist promotes Th17 differentiation resulting in 
exacerbation of EAE.  
 
Th17 cells are required to clear microbial pathogens and maintain barrier function 
but inappropriate Th17 responses mediate autoimmune diseases.  AHR expression 
is significantly higher in Th17 cells compared to Treg cells, and AHR activation 
leads to both expansion and increased cytokine production by differentiated Th17 
cells although it seems dispensable for Th17 differentiation under certain 
experimental conditions. In line with this, Veldhoen et al showed that FICZ activated 
AHR under Th17 polarizing condition (IL-6 and TGF-β1) in vitro to induce the 
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differentiation of naïve CD4+ T cells to a Th17 phenotype marked by up-regulated 
IL-17A, IL-17F and IL-22 mRNA expression, sufficient to exacerbate EAE in vivo 
[26]. AHR-deficient mice on the other hand under similar conditions had attenuated 
IL-17A and IL-17F secretion with no detectable IL-22 in presence or absence of 
FICZ [26]. Although these results have highlighted the essential role of AHR in Treg 
and TH17 cells, the mechanism by which AHR mediates this effect is largely 
unknown. This apparent paradox between FICZ and TCDD exposure in EAE 
suggests that AHR is activated in a ligand specific manner which differentially 
regulates Th17 vs Treg differentiation [27]. Thus, AHR fine-tunes the Treg/Th17 
balance based on the cytokine milieu in the cellular microenvironment in a ligand 
specific manner. Also, silencing of the IL-2 locus is critical for development of Th17 
cells, and it has been shown that under Th17 polarizing conditions this is mediated 
by induction of Aiolos, a member of Ikaros family of transcription factors, by Stat3 
and AHR. In addition to this, activation of AHR in dendritic cells by an endogenous 
AHR ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) 
induces tolerogenic dendritic cells in a retinoic acid dependent manner to promote 
differentiation of Foxp3+ Treg cells. Environmental factors are linked to autoimmune 
disorders and involvement of AHR in Treg/Th17 differentiation and function opens 
up new avenues for the treatment of these disorders. 
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1.6 Identification of a DRE-independent pathway 
Recently, it was shown that AHR can regulate NFκB regulated gene expression 
especially acute phase genes such as serum amyloid A (Saa). Acute phase genes 
are induced due to environmental stress, inflammation or neoplastic growth and a 
sustained induction is unwarranted and deleterious. Although acute phase proteins 
(APP) like serum amyloid A, plasminogen and C-reactive protein (CRP) that are 
made in liver are required as a first line of defense, in chronic inflammatory settings 
such as autoimmune diseases these proteins can have detrimental effects on 
immune signaling, amylodoisis and catabolism. AHR activation by certain ligands 
has been shown to suppress Saa, which are induced in response to cytokines in 
liver, suggesting AHR is a potential therapeutic target for treatment of chronic 
inflammatory/autoimmune diseases. However, ligand bound AHR requires nuclear 
translocation with AHR-nuclear translocator and heterodimerization but it does not 
require DNA binding to suppress Saa expression. Thus activation of AHR 
bypassing the DRE-mediated DNA binding pathway can lead to the suppression of 
acute phase genes, which opens up new avenues in the treatment of chronic 
inflammatory conditions, like cancer and autoimmune diseases. 
 
1.7 Why study Selective AHR modulators (SAHRMs) 
Selective AHR modulators (SAHRMs) are a recently identified class of compounds 
that are capable of binding to AHR without activating DRE-driven responses. An 
agonist activates both DRE and non-DRE pathways while an antagonist inhibits both 
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of them but a partial antagonist It selectively inhibits only the DRE- mediated 
pathway while  the non-DRE driven responses remain unaffected (Fig.5). These 
compounds are interesting therapeutically as they can potentially be used to inhibit 
DRE-mediated transcription while inducing anti-inflammatory or other non-DRE AHR 
dependent responses. A number of reports have highlighted the adverse effect of a 
sustained AHR activation with AHR agonists, which results in increased 
inflammation. However, recently it was shown that AHR activation can also lead to 
anti-inflammatory responses by interacting with NFκB signaling or suppressing 
proinflammatory cytokines like IL-6 and this pathway is independent of its ability to 
bind DNA (DRE-mediated pathway), a non-DRE-mediated/non-canonical AHR 
pathway. Since, sustained activation of AHR by DRE-mediated pathway leads to a 
toxic response, activation of AHR without affecting DRE-mediated responses can be 
beneficial as it can suppress the induction of acute phase genes without cellular 
toxicity. The potential role of SAHRMs is gaining momentum due to the recent 
findings that AHR can be modulated to affect disease pathophysiology. Firstly, 
suppressing AHR by AHR antagonist can inhibit Th17 cell development, which is the 
prime mediator of autoimmune diseases like rheumatoid arthritis and multiple 
sclerosis. Secondly, as aforementioned, activation of AHR via the non-canonical 
pathway bypassing the DRE- mediated pathway can lead to the suppression of 
acute phase genes like Saa that promote inflammation and amyloidosis, and lastly 
modulating AHR selectively can also affect estrogenic activity in breast cancer 
patients. Hence, SAHRMs are an attractive strategy to modulate AHR for treatment 
of these chronic diseases.  However, an agonist will globally activate AHR through 
15 
 
the activation of DRE-mediated pathway leading to a toxic response, while a 
complete antagonist will suppress both the deleterious effects of DRE activation and 
the beneficial anti-inflammatory effects of the non-DRE mediated pathway. 
 
Fig. 5.  Activation or inhibition of DRE and non-DRE mediated AHR pathway. 
AHR can be activated by both DRE and non-DRE mediated pathways by an AHR agonist 
whereas a complete antagonist would inhibit both. The SAHRMs on the other hand can 
selectively activate AHR only by the non-DRE mediated pathway but inhibits the DRE- 
driven responses. 
 
In this study we have explored potential of AHR modulation by selective or global 
activation by SAHRMs and agonists respectively as well as inhibition of AHR by a 
complete antagonist in regulation of T helper cell responses. This thesis is driven by 
the central hypothesis that regulating AHR with AHR ligands can modulate Th17 
versus Treg differentiation to control pro- versus anti-inflammatory responses in 
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vivo.  We will achieve this by working on the following specific aims: 1. Determine 
the role of the AHR in T cell differentiation by using AHR ligands that 
modulate the AHR pathway. We hypothesize that the selective AHR modulators 
(SAHRMs) will modulate AHR activity and affect T cell differentiation. Our 
preliminary data suggests modulating AHR with SAHRMs in CD4+T cells affects 
Th17 and Treg differentiation in vitro.  2. Determine the effect of AHR modulation 
by SAHRMs on T-helper cell plasticity in vivo. We hypothesize that the 
terminally differentiated T-helper cells will be skewed in the presence of SAHRMs.  
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CHAPTER 2 
 
 
 
Role of aryl hydrocarbon receptor (AHR) and the 
effect of selective AHR modulators (SAHRMs) on 
T cell differentiation 
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2.1 Introduction 
A naïve CD4+ T cell upon antigenic stimulation can differentiate into at least four 
different subset of T helper lineages namely Th1, Th2, Th17 and Treg cells [1-3]. Th1 
cells are characterized by secretion of IFN- upon stimulation by intracellular antigens 
and the Th1 lineage program is regulated by the master transcription factor T-bet. 
Extracellular parasites induce naïve CD4+ T cells to upregulate GATA3 and differentiate 
Th2 cells that can secrete IL-4, IL-5 and IL-13. Th17 cells are induced by extracellular 
bacteria and fungi to secrete IL-17A or eponymous cytokine IL-17F along with 
upregulation of RORt [4]. Treg cells on the other hand suppress aberrant immune 
responses by expressing Foxp3 and secreting anti-inflammatory cytokines like IL-10 
and TGF-.   
 
The aryl hydrocarbon receptor (AHR) is a type I nuclear receptor that is expressed in 
both Th17 and Treg albeit at higher proportion in Th17 than in Tregs or any other Th cell 
subset. AHR agonist TCDD or dioxin promotes differentiation of CD25+Foxp3+Treg cells 
and suppresses EAE, whereas the tryptophan photoproduct 6-formylindolo[3,2-b] 
carbazole (FICZ), an endogenous ligand of AHR, induces IL-17A resulting in 
exacerbation of EAE [6-8]. However, in AHR knockout mice there was minimal defect in 
generation of Treg or Th17 cells but Th17 cells were defective in the secretion of IL-22, 
a cytokine co-expressed with IL-17A and is required for mucosal immunity and secretion 
of anti-microbial peptides [4, 6, 7, 9]. A better understanding of this apparent 
dichotomous behavior of AHR ligands could be useful in identifying links between 
environmental ligands of AHR, including toxins, and the development of autoimmune 
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diseases. AHR may be activated via two pathways, a DRE- mediated DNA binding 
pathway or via non-DRE mediated protein-protein interaction [10-12]. Based on how 
AHR is activated, it can result in very different outcomes [13-19].  An agonist would 
activate both DRE and non-DRE pathways, whereas an antagonist inhibits both [10, 
12]. On the other hand, a partial antagonist like SGA-360 would selectively inhibit the 
DRE- driven downstream effects and activate the non-DRE mediated pathway. 
Recently, it has been shown that selectively activating AHR by inhibiting the DRE-driven 
activity can be beneficial in repression of cytokine mediated acute phase genes like 
serum amyloid A (saa) which can be detrimental in chronic inflammatory diseases like 
rheumatoid arthritis [11, 20, 21]. 
Selective AHR modulators (SAHRMs) are a recently identified class of compounds that 
are capable of binding to AHR, activating non-DRE-driven responses without inhibiting 
the DRE driven responses [11]. These compounds are interesting therapeutically as 
they can be used to inhibit the DRE-mediated pathway while promoting other functions 
of the AHR, including anti-inflammatory responses through the non DRE-mediated 
pathway [11]. It has been shown that activation of naïve CD4+ T cells under Th17 
inducing conditions strongly upregulated the expression of AHR [6, 8]. In this study, we 
have used a partial/selective antagonist called SGA-360, which blocks the DRE function 
of AHR  while selectively activating the non-DRE functions of AHR [11]. We have also 
examined the functions of other complete agonists of AHR, TCDD, FICZ and β-NF 
(beta-naphthoflavone) [6-8, 22] . We have also used a complete antagonist, GNF, which 
antagonizes both the DRE-mediated and acute-phase gene repression activities of AHR 
[12]. Here we show that, agonist and antagonist ligands of AHR differentially affect the 
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differentiation of Th17 and Treg cells. More importantly, the effect of agonist on 
differentiation of Th17 and Treg cells was ligand specific. We also find that, under Th17 
polarizing conditions, IL-17A expression under Th17 polarizing condition was promoted 
by the activation of AHR through the canonical AHR pathway while suppression of the 
non-canonical non-DRE mediated AHR pathway resulted in the suppression of Foxp3 
under Treg skewing conditions. 
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2.2 Results 
2.2.1 Selective inhibition of the DRE pathway is sufficient to inhibit IL-17A 
To determine the effect of AHR ligands on the differentiation of effector CD4+ T cells in 
vitro we stimulated splenocytes from OTII mice (transgenic mice in which CD4+ T cells 
express a TCR which can recognize chicken Ovalbumin) with Ovalbumin (OVA) peptide 
(OVA 323-339) in the presence of SAHRM SGA-360, a partial antagonist, or β-NF, an 
AHR agonist.  The addition of SGA-360 under non-skewing Th0 condition, suppressed 
the induction of Cyp1A1, a known downstream target of AHR [23]. Inhibition of DRE 
activity of AHR by SGA-360 resulted in an increase in the expression of IL-4 but did not 
alter the expression of IL-17A or the Th1, Th2 and Th17 lineage defining transcription 
factors T-bet, Gata3 and RoRγt. On the other hand, under similar conditions β-NF 
enhanced Cyp1A1, IL-17A, RoRγt, and suppressed IL-4 and Gata3 gene expression 
(Fig.1A). In line with this, β-NF increased IL-17A and suppressed IL-4 cytokine 
secretion, in contrast to SGA-360, which suppressed the secretion of IL-17A and IFN-γ 
while inducing the production of IL-4 (Fig.1B). This suggests that modulating AHR 
activity by SAHRMs during T cell activation can differentially affect their ability to secrete 
effector cytokines, for instance the ability of CD4+ T cells to make IL-17A upon activation 
even in the absence of Th17 polarizing conditions. 
25 
 
 
 
A Cyp1A1 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
1
2
3
R
el
at
iv
e 
ex
pr
es
si
on ***
**
IL-17A
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
5
10
15
20
25
R
el
at
iv
e 
ex
pr
es
si
on **
IL-4 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
100
200
300
400
R
el
at
iv
e 
ex
pr
es
si
on
*
**
GATA3 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
20
40
60
80
Re
la
tiv
e 
ex
pr
es
si
on
*
RORt 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0.0
0.5
1.0
1.5
R
el
at
iv
e 
ex
pr
es
si
on
*
T- bet 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
5
10
15
R
el
at
iv
e 
ex
pr
es
si
on
IFN 
O
va
O
va
+
-N
F
O
va
+S
G
A
-3
60
0
500
1000
1500
R
el
at
iv
e 
ex
pr
es
si
on
**
B IFN 
O
va
O
va
+
N
F
O
va
+S
G
A
-3
60
0
1000
2000
3000
4000
5000
pg
/m
l
*
IL-17A
O
va
O
va
+
N
F
O
va
+S
G
A
-3
60
0
50
100
150
200
*
pg
/m
l
IL-4 
O
va
O
va
+
N
F
O
va
+S
G
A
-3
60
0
50
100
150
200
**
pg
/m
l
*
26 
 
Fig. 1. Selective inhibition of the DRE pathway is sufficient to inhibit IL-17A. A) 
qPCR analysis of WT OTII splenocytes and lymph node cells that were stimulated with OVA-
peptide (323-339) in IMDM media for 5 days in the presence of β-naphthoflavone (2 μM) or 
SGA-360 (2 μM) and analyzed for the indicated genes. B) Supernatants from cells treated as in 
A was analyzed for the indicated cytokines by multiplex cytokine assay. Data represents 
Mean±SEM of n≥3 mice, *p<0.05 by paired students t test.  
 
2.2.2 AHR ligands influence Th17 differentiation via the DRE-driven pathway  
It has been shown that AHR is induced during Th17 polarizing conditions and AHR is 
known to act as a regulator of Th17 differentiation in a ligand specific manner [6, 7, 13]. 
We compared the effect of AHR agonists β-NF, FICZ, TCDD and antagonist GNF along 
with SAHRM, SGA-360 under Th17 polarizing condition to determine their ability to 
modulate CD4+ T cell differentiation into Th17 cells. To this end, we isolated naïve CD4+ 
T cells from IL-17A-GFP reporter mice (transgenic mice containing an IRES-EGFP 
sequence inserted downstream of the stop codon of IL-17A gene) and stimulated them 
under Th17 polarizing conditions with IL-6 and transforming growth factor (TGF-β). This 
reporter model is a useful tool to evaluate the differentiation of Th17 cells (percentage of 
GFP+ cells) as well as the amount of IL-17A produced on a per cell basis (mean 
fluorescence intensity [MFI] of GFP among GFP+ cells). AHR agonist, FICZ induced 
both differentiation of Th17 cells and production of IL-17A. β-NF could affect only the 
frequency of  Th17 cells and TCDD only the MFI of IL17-A. These results suggests that 
the activation of DRE- mediated pathway to modulate the frequency of CD4+ Th17 cells 
or their ability to make IL-17A on a per cell basis is a ligand dependent process 
(Fig.2A,B).  
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Fig. 2. AHR ligands influence Th17 differentiation via the DRE-driven pathway. 
Naïve CD4+ T cells isolated from IL-17A-GFP reporter mice were cultured for 3 days with α-
CD3/CD28 under Th17 skewing condition in the presence or absence 2 μM of β-naphthoflavone 
(β-NF) (A), 100 nM of 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) (B) or 200 nM of 6-Formylindolo 
(3,2-b) carbazole (FICZ). The cells were analyzed for the frequency of GFP+ cells (left panel) 
and for the mean fluorescence intensity (MFI) of GFP (right panel) by on the indicated time 
points flow cytometry. Representative plot of atleast 3 independent experiments. Data 
represents Mean±SEM of n≥3 mice, *p<0.05 by 2-way ANOVA. 
 
On the other hand, under similar conditions SGA-360 suppressed both frequency of 
Th17 cells and the MFI of IL-17A, which is in contrast to the complete antagonist GNF 
that only suppressed the frequency of Th17 cells. (Fig.3 A & B). These results suggest 
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that selectively inhibiting just the DRE mediated canonical AHR pathway can suppress 
the differentiation of naïve CD4+ T cells into the Th17 lineage, indicating that regulation 
of IL-17A is mediated by DRE dependent pathway.  
 
Fig. 3. AHR ligands influence Th17 differentiation via the DRE-driven pathway. 
Naïve CD4+ T cells isolated from IL-17A-GFP reporter mice were cultured for 3 days with α-
CD3/CD28 under Th17 skewing condition in the presence or absence 2 μM of SGA-360 (A), 
100 nM of GNF (B) or 200 nM of 6-Formylindolo (3,2-b) carbazole (FICZ). The cells were 
analyzed for the frequency of GFP+ cells (left panel) and for the mean fluorescence intensity 
(MFI) of GFP (right panel) on the indicated time points by flow cytometry. Representative plot of 
atleast 3 independent experiments. Data represents Mean±SEM of n≥3 mice, *p<0.05 by 2-way 
ANOVA. 
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We also analyzed the effects of these compounds on already differentiated Th17 cells in 
vitro. To this end, we added the compounds after differentiation of naïve CD4+ T cells 
into Th17 cells and found that though β-NF could significantly increase the frequency of 
Th17 cells beyond that seen with FICZ, there was no difference in the amount of IL-17A 
produced on a per cell basis (Fig.4 A). On the other hand TCDD increased both the 
frequency IL-17A+ cells and the MFI of IL-17A in already differentiated Th17 cells 
suggesting that the AHR agonists β-NF and TCDD differentially regulates IL-17A 
expression in Th17 versus naïve CD4+ T cells. (Fig.4 B). Neither SGA-360 nor GNF 
could modulate the expression of IL-17A under these conditions (Fig.4 C & D). This 
suggests that, while agonists of AHR could further enhance IL-17A responses, inhibiting 
only the DRE-mediated activity of AHR or both the DRE and non-DRE activity does not 
affect the expression of IL-17A by already differentiated Th17 cells. 
 
 
 
 
DMSO
BNF(ag)
FICZ(ag)
0 1 2 3 4
0
2000
4000
6000
8000
10000
Days
M
FI
- I
L1
7A
-G
FP
0 1 2 3 4
0
20
40
60
80
100
**
Days
Pe
rc
en
t C
D
4+
TC
R
+ I
L-
17
G
FP
+  A
30 
 
 
 
Fig. 4. AHR ligands influence Th17 differentiation via the DRE-driven pathway. 
Naïve CD4+ T cells isolated from IL-17A-GFP reporter mice were cultured for 3 days with α-
CD3/CD28 under Th17 skewing condition and subsequently restimulated under Th17 skewing 
condition in the presence or absence 2 μM of β-naphthoflavone (β-NF) (A), 100 nM of 2,3,7,8-
Tetrachlorodibenzodioxin (TCDD) (B), 2 μM of SGA-360 (C), 100 nM of GNF (D) or 200 nM of 
6-Formylindolo (3,2-b) carbazole (FICZ) for 3 days. The cells were analyzed for the frequency of 
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GFP+ cells (left panel) and for the mean fluorescence intensity (MFI) of GFP (right panel) on the 
indicated time points by flow cytometry. Representative plot of atleast 3 independent 
experiments. Data represents Mean±SEM of n≥3 mice, *p<0.05 by 2-way ANOVA. 
 
2.2.3 Foxp3 expression is regulated by both DRE and non-DRE driven AHR 
activity under Treg polarizing condition 
Similar to Th17 differentiation, AHR is also induced during Treg differentiation [6] . This 
prompted us to investigate the role of these compounds on the differentiation of naïve 
CD4+ T cells into Tregs. We found that the AHR agonist behaved differently in affecting 
differentiation of Tregs as assessed by induction of Foxp3 expression by CD4+ T cells. 
TCDD and FICZ both induced whereas β-NF had no effect on this process. Inhibiting 
only the DRE- driven activity by SGA-360 had no effect on the differentiation of Tregs 
but inhibiting both DRE and non-DRE mediated AHR activity with GNF inhibited Treg 
differentiation (Fig.5). This suggests that inhibition of the DRE- independent pathway 
can suppress induction of Foxp3 under Treg skewing conditions is mediated by 
inhibition of the DRE-independent pathway. It is interesting to note that even under Treg 
polarizing conditions β-NF and FICZ increased the frequency of the IL-17A+ CD4+ T 
cells (Fig.6 A). Under these conditions TCDD, SGA-360 and GNF did not induce IL-
17A. (Fig.6 B, C & D). 
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Fig. 5. Foxp3 expression is regulated by both DRE and non-DRE driven AHR 
activity under Treg polarizing condition. Naïve CD4+ T cells isolated from IL-17A-GFP 
reporter mice were cultured for 3 days with α-CD3/CD28 under Treg skewing condition in the 
presence or absence 2 μM of β-naphthoflavone (β-NF), 100 nM of 2,3,7,8-
Tetrachlorodibenzodioxin (TCDD), 2 μM of SGA-360, 100 nM of GNF or 200 nM of 6-
Formylindolo (3,2-b) carbazole (FICZ). The cells were analyzed for the frequency of Foxp3+ 
cells by flow cytometry. Data represents Mean±SEM of 2 independent experiments with n≥3 
mice per experiment, *p<0.05 by paired students t test. 
 
 
D
M
SO
B
N
F 
(a
g)
SG
A
 (p
-a
nt
-a
g)
G
N
F 
(a
nt
-a
g)
FI
C
Z 
(a
g)
TC
D
D
 (a
g)
0
10
20
30
40
*****
*
 
Pe
rc
en
t C
D
4+
TC
R
+ F
ox
p3
+  T
 c
el
ls
33 
 
 
0 1 2 3 4
0
500
1000
1500
Days
M
FI
- I
L1
7A
-G
FP
0 1 2 3 4
0
10
20
30
40
50
DMSO 
BNF(ag)
FICZ(ag)
**
Days
Pe
rc
en
t C
D
4+
TC
R
+ I
L-
17
G
FP
+  
0 1 2 3 4
0
500
1000
1500
Days
M
FI
- I
L1
7A
-G
FP
0 1 2 3 4
0
10
20
30
40
50
DMSO 
FICZ(ag)
TCDD(ag)
Days
Pe
rc
en
t C
D
4+
TC
R
+ I
L-
17
G
FP
+  
0 1 2 3 4
0
500
1000
1500
Days
M
FI
- I
L1
7A
-G
FP
0 1 2 3 4
0
10
20
30
40
50
DMSO 
SGA(p-ant-ag)
FICZ(ag)
DAYS
Pe
rc
en
t C
D
4+
TC
R
+ I
L-
17
G
FP
+  
0 1 2 3 4
0
500
1000
1500
2000
Days
M
FI
- I
L1
7A
-G
FP
0 1 2 3 4
0
10
20
30
40
50
DMSO 
GNF(ant-ag)
FICZ(ag)
Days
Pe
rc
en
t C
D
4+
TC
R
+ I
L-
17
G
FP
+  
A
B
C
D
34 
 
Fig. 6. -NF and FICZ promotes IL-17A expression under Treg polarizing condition. Naïve CD4+ T 
cells isolated from IL-17A-GFP reporter mice were cultured for 3 days with α-CD3/CD28 under Treg 
skewing condition in the presence or absence 2 μM of β-naphthoflavone (β-NF) (A), 100 nM of 2,3,7,8-
Tetrachlorodibenzodioxin (TCDD) (B), 2 μM of SGA-360 (C), 100 nM of GNF (D) or 200 nM of 6-
Formylindolo (3,2-b) carbazole (FICZ). The cells were analyzed for the frequency of GFP+ cells (left 
panel) and for the mean fluorescence intensity (MFI) of GFP (right panel) on the indicated time points by 
flow cytometry. Representative plot of atleast 3 independent experiments. Data represents Mean±SEM of 
n≥3 mice, *p<0.05 by 2-way ANOVA. 
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2.3 Discussion 
AHR has been shown to act as a sensor for environmental toxins such as dioxin, 
polycyclic halogenated compounds and structurally related compounds [24, 25]. It is 
becoming increasingly clear that AHR also plays an important role in the regulation of 
signaling in immune cells. Also, it is well known that environmental and dietary 
compounds that are AHR ligands play important roles in the induction of immune cell 
mediated inflammatory and autoimmune diseases and hence modulation of AHR is 
attractive as a strategy for control of these diseases [11]. Recent studies have identified 
AHR as having dual roles in the regulation of Th17 and Treg responses dependent on 
the ligand. It is known that Treg and Th17 cells have reciprocal relationship in their 
differentiation and AHR has been shown to be one of the common transcription factors 
that can regulate differentiation in the two cell populations [6].  In this study we have 
used three agonists TCDD, FICZ and β-NF to elucidate the effects of AHR activation on 
their effect on Th17/ Treg differentiation in vitro. Our findings indicate that AHR agonists 
have very different effects on the differentiation of Th17. FICZ, was able to enhance 
naïve CD4+ T cell differentiation towards a Th17 phenotype and induce the expression 
of IL-17A, whereas β-NF could only enhance the frequency of Th17 cells. This shows 
that β-NF is able to drive a higher number of naïve CD4+ T cells towards a Th17 
phenotype but was unable enhance the production of IL-17A cytokine. By contrast, 
TCDD which is known to activate AHR to selectively upregulate FoxP3 in CD4+ T cells 
under Treg polarizing conditions, was able to drive enhanced production of IL-17A 
cytokine on a per cell basis without increasing the frequency of Th17 cells under Th17 
polarizing conditions.  
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Altogether these data suggest that AHR agonists may bind to distinct co-factors or 
differentially activate downstream signaling pathways, with resultant differences in the 
ability to regulate differentiation of Th17 cells and IL-17A production by Th17 cells. On 
the other hand, we found that both the complete antagonist GNF and the partial 
antagonist SGA-360 inhibited the differentiation of naïve CD4+T cells into Th17 cells 
confirming the involvement of AHR activation in the process. We also examined the 
effects of these compounds on already differentiated Th17 cells and found that FICZ 
and TCDD could increase both the frequency and IL-17A expression from Th17 cells 
but β-NF only increases the frequency of Th17 cells which shows these agonists can 
further promote IL-17A secretion by terminally differentiated Th17 cells. Under the same 
conditions neither SGA-360 nor GNF had any effect on the frequency of IL-17A+ cells as 
well as the secretion of IL-17A showing that DRE-mediated suppression is not effective 
on already lineage committed Th17 cells. 
TCDD has been shown to have immunosuppressive effects by activating AHR and 
promoting Treg cell differentiation, via direct regulation of Foxp3 expression [6]. In this 
study we have identified the differential effects of the AHR ligands under T regulatory 
cell polarizing conditions. We found that the agonists TCDD and FICZ can promote 
Tregs from naïve CD4+ T cells, whereas β-NF neither inhibited nor promoted the Treg 
cell differentiation. This indicates that β-NF may regulate AHR to modulate Foxp3 via a 
different mechanism than that of FICZ or TCDD even though all of them activate AHR 
through a DRE-mediated pathway. The partial antagonist SGA-360 had no effect on the 
differentiation of Tregs but the complete antagonist GNF suppressed it, suggesting that 
non-DRE mediated AHR activation may be able to suppress expression of Foxp3. In 
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other words, the regulation of Foxp3 expression by AHR can be mediated both by the 
DRE and non-DRE-driven responses dependent on the ligand. This suggests that AHR 
agonist and antagonist compounds can not only differentially regulate Th17 versus Treg 
differentiation but could also potentially influence the function of differentiated cells by 
controlling the frequency or the amount of IL-17A produced by these cells. These 
results further underscore the ligand specific functions of these compounds in the 
generation and/or function of Th17 and Treg cells. This is interesting because to our 
knowledge this is the first report that suggests a role for AHR signaling in the regulation 
of CD4+ T cell plasticity.  
Our results suggest that AHR activation can result in different outcomes in a ligand 
specific manner. It is known that AHR can interact with other transcription factors like 
cMaf, Stat1 to regulate different subsets of CD4+T cells [26]. AHR is known to have 
crosstalk with receptors like estrogen and retinoic acid receptors, which may influence 
the dichotomous behavior of AHR in a ligand specific manner to modulate the 
Th17/Treg balance in a ligand specific manner.  Thus ligand specific modulation of AHR 
makes it an attractive therapeutic target for the treatment autoimmune and chronic 
inflammatory diseases that have a strong correlation with environmental toxins and 
disregulation of Th17/Treg balance. 
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2.4 Materials and Methods 
2.4.1 Mice and treatments. OTII and IL17A-GFP reporter mice were purchased from 
Jackson laboratories and Biocytogen respectively. All mice were used between 6- and 
12-wk of age and maintained in a specific pathogen free environment. All experiments 
were performed in accordance with the regulations of the Office of Research 
Protection’s Institutional Animal Care and Use Committee at Cornell University and the 
National Institutes of Health. 
 
2.4.2 Cytokine analysis. OTII splenocytes and lymph node cells were cultured in IMDM 
media at 2million/ml concentration in triplicate and except the media control, all wells 
were added ovalbumin (Sigma) at 10ug/ml and compounds β-NF and SGA 360 at 5μM 
on the first day of the culture. 5 days later the supernatants were collected and the 
cytokines were quantified by Bioplex a Luminex system (Bio-Rad) with Milliplex plates 
(Millipore). 
 
2.4.3 Quantitative PCR. RNA was extracted either using TRIZOL reagent (Invitrogen) 
or using the RNAeasy kit (Invitrogen) and cDNA was generated with a kit from You 
Prime First-Strand beads kit (GE Biosciences). q-PCR was then performed with all 
values normalized to respective GAPDH values and the data expressed as 2-
DDCt (where Ct is threshold cycle), the values are represented as fold change over 
respective controls. 
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2.4.4 T cell purification and polarizing conditions. Naïve T cells 
(CD4+TCR+CD44lowCD62Lhigh) were isolated from spleens and lymph nodes of IL-17A 
reporter mice using Naïve CD4+ T cell isolation kit from Miltenyi Biotech using 
manufacturers recommendations. Th17 polarizing conditions included 1 g/mL -
murine CD3 and 3 g/mL -murine CD28 (BD Biosciences), 20 ng/mL IL6, 5 ng/mL 
TGF1 (Peprotech) and 10 g/mL of -IFN-. Treg polarizing conditions included 1 
g/mL -murine CD3 and 3 g/mL -murine CD28 (BD Biosciences), 5ng/mL of 
TGF1, 25 ng/mL of IL-2 (Peprotech) and 10 g/mL of -IFN-.  Cells were cultured in 
IMDM media (Sigma). 
 
2.4.5 Analysis of transcription factors and flow cytometry. Foxp3 fixation/ 
permeabilization kit (eBioscience) was used to fix/ permeabilize cells and then stained 
for the indicated surface proteins, and transcription factors. LSRII flow cytometer (BD 
Biosciences) was used to acquire data and the data was analyzed with FlowJo 
(TreeStar). 
 
 2.4.6 Data analysis. Statistical analysis was done with Student’s t test and  two-way 
ANOVA using GraphPad Prism version 5.00 for Windows (GraphPad, San Diego, CA).  
Differences with probability p ≤ 0.05 were considered statistically significant. 
 
 
 
 
40 
 
2.5 References 
 
1. Weaver, C.T., et al., The Th17 pathway and inflammatory diseases of the 
intestines, lungs, and skin. Annu Rev Pathol, 2013. 8: p. 477-512. 
2. Vahedi, G., et al., Helper T-cell identity and evolution of differential 
transcriptomes and epigenomes. Immunol Rev, 2013. 252(1): p. 24-40. 
3. Naito, T. and I. Taniuchi, Roles of repressive epigenetic machinery in lineage 
decision of T cells. Immunology, 2013. 139(2): p. 151-7. 
4. Peters, A., Y. Lee, and V.K. Kuchroo, The many faces of Th17 cells. Curr Opin 
Immunol, 2011. 23(6): p. 702-6. 
5. Weaver, C.T. and R.D. Hatton, Interplay between the TH17 and Treg cell 
lineages: a (co-)evolutionary perspective. Nat Rev Immunol, 2009. 9(12): p. 883-
9. 
6. Quintana, F.J., et al., Control of T(reg) and T(H)17 cell differentiation by the aryl 
hydrocarbon receptor. Nature, 2008. 453(7191): p. 65-71. 
7. Veldhoen, M., et al., The aryl hydrocarbon receptor links TH17-cell-mediated 
autoimmunity to environmental toxins. Nature, 2008. 453(7191): p. 106-9. 
8. Kimura, A., et al., Aryl hydrocarbon receptor regulates Stat1 activation and 
participates in the development of Th17 cells. Proc Natl Acad Sci U S A, 2008. 
105(28): p. 9721-6. 
9. Garrido-Mesa, N., et al., Functional plasticity of Th17 cells: implications in 
gastrointestinal tract function. Int Rev Immunol, 2013. 32(5-6): p. 493-510. 
10. Beischlag, T.V., et al., The aryl hydrocarbon receptor complex and the control of 
gene expression. Crit Rev Eukaryot Gene Expr, 2008. 18(3): p. 207-50. 
41 
 
11. Murray, I.A., et al., Development of a selective modulator of aryl hydrocarbon 
(Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res 
Toxicol, 2010. 23(5): p. 955-66. 
12. Smith, K.J., et al., Identification of a high-affinity ligand that exhibits complete aryl 
hydrocarbon receptor antagonism. J Pharmacol Exp Ther, 2011. 338(1): p. 318-
27. 
13. Stevens, E.A. and C.A. Bradfield, Immunology: T cells hang in the balance. 
Nature, 2008. 453(7191): p. 46-7. 
14. Negishi, T., et al., Effects of aryl hydrocarbon receptor signaling on the 
modulation of TH1/TH2 balance. J Immunol, 2005. 175(11): p. 7348-56. 
15. Baba, N., et al., The aryl hydrocarbon receptor (AHR) ligand VAF347 selectively 
acts on monocytes and naive CD4(+) Th cells to promote the development of IL-
22-secreting Th cells. Hum Immunol, 2012. 73(8): p. 795-800. 
16. Baban, B., J.Y. Liu, and M.S. Mozaffari, Aryl hydrocarbon receptor agonist, 
leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem 
cells. Am J Physiol Regul Integr Comp Physiol, 2012. 303(11): p. R1136-46. 
17. Quintana, F.J., et al., An endogenous aryl hydrocarbon receptor ligand acts on 
dendritic cells and T cells to suppress experimental autoimmune 
encephalomyelitis. Proc Natl Acad Sci U S A, 2010. 107(48): p. 20768-73. 
18. Jeong, K.T., et al., FICZ, a tryptophan photoproduct, suppresses pulmonary 
eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-
induced allergic asthma. Int Immunopharmacol, 2012. 13(4): p. 377-85. 
19. Rohlman, D., et al., Suppression of acute graft-versus-host response by TCDD is 
independent of the CTLA-4-IFN-gamma-IDO pathway. Toxicol Sci, 2013. 135(1): 
p. 81-90. 
42 
 
20. McInnes, I.B., et al., Effect of interleukin-6 receptor blockade on surrogates of 
vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-
controlled study. Ann Rheum Dis, 2013. 
21. Deguchi, A., et al., Serum amyloid A3 binds MD-2 to activate p38 and NF-
kappaB pathways in a MyD88-dependent manner. J Immunol, 2013. 191(4): p. 
1856-64. 
22. Wang, C., et al., Beta-naphthoflavone (DB06732) mediates estrogen receptor-
positive breast cancer cell cycle arrest through AHR-dependent regulation of 
PI3K/AKT and MAPK/ERK signaling. Carcinogenesis, 2013. 
23. Nebert, D.W. and C.L. Karp, Endogenous functions of the aryl hydrocarbon 
receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized 
eicosanoids and AHR biology. J Biol Chem, 2008. 283(52): p. 36061-5. 
24. Stevens, E.A., J.D. Mezrich, and C.A. Bradfield, The aryl hydrocarbon receptor: a 
perspective on potential roles in the immune system. Immunology, 2009. 127(3): 
p. 299-311. 
25. Fujii-Kuriyama, Y. and K. Kawajiri, Molecular mechanisms of the physiological 
functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that 
senses and responds to environmental stimuli. Proc Jpn Acad Ser B Phys Biol 
Sci, 2010. 86(1): p. 40-53. 
26. Gandhi, R., et al., Activation of the aryl hydrocarbon receptor induces human 
type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol, 2010. 
11(9): p. 846-53. 
 
 
43 
 
 
 
 
 
 
Chapter 3 
 
 
Regulation of Th17 responses in acute and chronic inflammatory 
diseases by AHR ligands 
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3.1 Introduction 
Th17 cells are a distinct subtype of CD4+ T cells which secrete cytokines like IL-17A, IL-
17F, IL-21, IL-22 and mediate autoimmune pathologies like experimental autoimmune 
encephalitis (EAE), collagen-induced arthritis (CIA) and psoriasis [1-3]. While Th17 cells 
have been well characterized for their pro-inflammatory role, they also play a protective 
role in the clearance of extracellular pathogens and fungi by promoting neutrophil 
recruitment and IgG mediated opsonization [4]. In the gut, depending on the cytokine 
environment, Th17 cells can mediate protective function by promoting gut barrier 
function and enhancing antimicrobial defense with the help of the co-expressed cytokine 
IL-22 [5, 6].  
C. rodentium is a gram-negative bacteria which causes distal colitis in the large intestine 
of mice and has been used as an in vivo murine model to study protective Th17 
responses. Infection is characterized by mucosal thickening and crypt hyperplasia due 
to epithelial cell proliferation. Upon oral infection, C. rodentium attaches to the epithelial 
cell surface (enterocytes) and induces the formation of the characteristic attachment/ 
effacement (A/E) lesion induced by enteropathogens that helps in effacement through 
the brush border microvilli and pedestal formation, which is very similar to 
enteropathogenic and enterohemorragic E. coli infection in humans [7, 8]. Colonic 
hyperplasia can be observed as early as 4 days post infection and the peak of the 
disease as assessed by bacterial burden is highest between days 10-12 post infection 
[7]. Both the epithelial cells that act as the first barrier to infection preventing trafficking 
of bacteria from the intestinal lumen and the adaptive immune system are critical for 
bacterial clearance [7]. In an immune-competent mouse, C. rodentium causes a 
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transient infection that is completely cleared by 14-21 days post infection with the 
induction of CD4+ T cell responses mainly driven by Th17 cells. Thus Th17 cells play a 
critical role in the protection against C. rodentium infection by promoting bacterial 
clearance.  AHR has been shown to play an important role in Th17 cell differentiation 
and we have recently shown that AHR can be modulated with agonist and antagonist 
compounds to regulate Th17 differentiation (refer to Chapter 2). Here we show that the 
addition of an AHR agonist, -NF during C. rodentium infection enhanced protective 
Th17 responses and promoted bacterial clearance. On the other hand, administration of 
an AHR partial antagonist, SGA-360 resulted in lower Th17 responses and higher 
bacterial burden at the early stages of C. rodentium infection.  
Hypersensitivity pneumonitis (also called extrinsic allergic alveolitis, EAA) is an 
inflammation of the alveoli within the lungs caused by hypersensitivity to aerosolized 
antigen. It is characterized by mononuclear infiltrates, collagen deposition and fibrosis in 
the lungs. Recent studies have shown Th17 driven processes mediates hypersensitivity 
pneumonitis [9, 10]. Using a chronic model of hypersensitivity pneumonitis induced by 
Saccharopolyspora rectivirgula (S. rectivirgula), we show that the agonist -NF 
enhanced IL-17A production by fully differentiated Th17 cells. The partial antagonist 
SGA-360 and complete antagonist GNF on the other hand had minimal effect on IL-17A 
production but promoted anti-inflammatory CD4+ T cell responses. This work has 
implications for better understanding of regulation of Th17 responses by AHR signaling. 
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3.2 Results 
3.2.1 β-NF protects mice against C. rodentium infection 
IL-17A produced by Th17 cells play a vital role in adaptive immune responses to protect 
against C. rodentium infection. We have shown in Chapter 2 that AHR agonist, β-NF, 
enhances the development of Th17 cells from naïve CD4+ T cells. We therefore 
hypothesized that β-NF, would promote mucosal Th17 responses to attenuate disease 
severity by aiding in bacterial clearance. It has been previously shown that upon C. 
rodentium infection mice develop minor weight loss due to diarrhea, one of the clinical 
signs of disease. Vehicle treated CR infected mice showed consistent reduction in body 
weight starting from 1 day post infection (DPI). By contrast, β-NF treated mice 
maintained their body weight throughout the course of infection (Fig1A). 
Upon infection, C. rodentium can be recovered in the fecal pellets of mice starting from 
4 DPI, a process referred to as bacterial shedding [11, 12] . In order to evaluate if 
administration of β-NF influenced bacterial burden, we monitored bacterial shedding at 
various time points post C. rodentium infection in vehicle or β-NF treated mice. Vehicle 
treated mice showed a typical pattern of bacterial burden with ~109 CFU of C. rodentium 
recovered per gram of feces at 6DPI.The bacterial burden peaked at 10 DPI reaching a 
maximum of around 2x109 CFU and this was completely cleared by 14 DPI. In line with 
our previous results that β-NF treated mice had no body weight loss, we observed that 
the bacterial burden was significantly lower at both 6 and 10 DPI in these mice. Also, 
there was a significant delay in the peak of bacterial shedding in β-NF treated mice with 
the highest bacterial burden at 14DPI (Fig1B). This suggests that administration of β-
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NF protects against C. rodentium infection by both delaying the peak and reducing 
bacterial burden in the large intestine. 
 
 
Fig. 1. β-NF protects mice against C. rodentium infection. A) IL17A-GFP reporter mice 
were infected with 5x109 CFUs of C. rodentium on day 1 and treated with vehicle control or 50 
mg/kg β-NF i.p. every other day starting from day 0 until the duration of the experiment and 
monitored for the change in body weight at the indicated time points represented as percent 
weight change (left panel) and linear regression analysis (right panel). B) Fecal pellets were 
collected from mice treated as above and analyzed for number of CFUs per gram of feces by 
plating dilutions on LB agar plates with Nalidixic acid. Representative plot of 3 independent 
experiments. Data represents Mean±SEM of n≥5 mice, *p<0.05 by 2 way ANOVA.  
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3.2.2 β-NF (agonist) promotes the differentiation of Th17 cells to protect against 
CR infection 
It has also been shown that Th17 driven responses are the major contributor of adaptive 
immunity to C. rodentium infection [13].In chapter 2 we showed that agonist and 
antagonist ligands of AHR can selectively regulate both Th17 differentiation and/ or IL-
17A production. To further confirm and extend these results in vivo, we infected IL-17A-
GFP reporter mice with C. rodentium and assessed the differentiation of Th17 cells in 
vivo in the presence of the AHR modulating compounds. To this end, we analyzed a 
number of gut associated organs including the small and large intestinal lamina propria, 
intraepithelial lymphocyte compartment, gut draining mesenteric lymph nodes and the 
peyers patch. The use of this IL-17A reporter model gives us a unique opportunity to 
analyze the induction of Th17 responses in vivo without the need for ex vivo stimulation. 
In line with published reports we find that upon C. rodentium infection TCR+ T cells 
were the major source of IL-17A+ GFP+ cells (Fig. 2A) and the induction of Th17 
responses to C. rodentium was the strongest in the large intestinal lamina propria, the 
primary site of infection 10 days post infection (Fig. 2B & 2C). This was further 
enhanced by the administration of -NF (Fig. 2B), suggesting that the enhanced 
bacterial clearance in these mice is due to enhanced development of Th17 responses. 
We did not find a significant difference between the proportion of Th17 cells in the small 
intestinal lamina propria, intraepithelial lymphocyte compartment, gut draining 
mesenteric lymph nodes and the peyers patch in the vehicle versus -NF treated mice 
suggesting that -NF induces a strong local Th17 response to C. rodentium (Fig. 2C). 
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Fig. 2. β-NF (agonist) promotes the differentiation of Th17 cells to protect against 
CR infection. IL17A-GFP reporter mice were infected with 5*10^9 CFUs of C. rodentium on 
day 1 and treated with vehicle control or 50 mg/kg β-NF i.p. every other day starting from day 0 
until the duration of the experiment and single cell suspensions obtained from large intestinal 
lamina propria (A & B), small intestinal lamina proria, intraepithelial lymphocytes, mesenteric 
lymph nodes and peyer’s patch (C) were analyzed for the expression of IL-17A-GFP by TCR+ 
(A) and CD4+ TCR+ cells (B & C). Representative flow plots shown in (A & B). Data represents 
Mean±SEM of n≥5 mice.  
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Fig. 2. β-NF (agonist) promotes the differentiation of Th17 cells to protect against 
CR infection. IL17A-GFP reporter mice were infected with 5*10^9 CFUs of C. rodentium on 
day 1 and treated with vehicle control or 50 mg/kg β-NF i.p. every other day starting from day 0 
until the duration of the experiment and single cell suspensions obtained from large intestinal 
lamina propria (A & B), small intestinal lamina proria, intraepithelial lymphocytes, mesenteric 
lymph nodes and peyer’s patch (C) were analyzed for the expression of IL-17A-GFP by TCR+ 
(A) and CD4+ TCR+ cells (B & C). Representative flow plots shown in (A & B). Data represents 
Mean±SEM of n≥5 mice.  
 
To further characterize the effect of -NF on the generation of Th17 responses in vivo in 
the presence of -NF we analyzed vehicle or -NF treated C. rodentium infected mice at 
c
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various time points post infection. We find that -NF treatment significantly enhanced 
Th17 responses to C. rodentium with the Th17 response highest at 10 DPI, the earliest 
time point we analyzed, as compared to vehicle treated controls that peaked at 14 DPI. 
There was no significant difference between the Th17 responses at 18 DPI between the 
vehicle and -NF treated mice suggesting that while activation of AHR promotes 
differentiation of Th17 cells it might not influence Th17 responses at later stages when 
the bacteria has been completely cleared showing that -NF only enhanced Th17 
responses during an active immune reaction (Fig. 3A). These GFP+ expressing CD4+ T 
cells represented the population of effector Th17 cells generated in response to C. 
rodentium, as we obtained a similar percentage of IL17A producing CD4+ T cells when 
we stimulated the large intestinal lamina propria cells isolated from mice at different 
stages of infection with PMA and Ionomycin ex vivo (Fig. 3B). We also found an inverse 
correlation between the magnitude of Th17 responses in the two groups and the 
abundance of bacteria in the fecal pellets (Compare Fig. 1B and Fig. 3A).Together 
these results suggest that activation of AHR by the agonist ligand -NF promotes Th17 
responses to protect against C. rodentium infection in mice. 
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Fig. 3. β-NF (agonist) promotes the differentiation of Th17 cells to protect against 
CR infection. IL17A-GFP reporter mice were infected with 5x109 CFUs of C. rodentium on day 
1 and treated with vehicle control or 50 mg/kg β-NF i.p. every other day starting from day 0 until 
the duration of the experiment and single cell suspensions obtained from large intestinal lamina 
propria were analyzed for the proportion of CD4+ TCRb+ that express IL-17A-GFP at the 
indicated time points (A) or stimulated for 5 hours with PMA/ Ionomycin in the presence of 
Brefeldin A and stained for the level of intracellular IL-17A in CD4+ TCRb+ cells at the indicated 
time points (B). Representative plot of 3 independent experiments. Data represents Mean±SEM 
of n≥5 mice, *p<0.05 by 2 way ANOVA.  
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infected mice at 10 DPI for Th17 responses. In line with increased bacterial burden we 
find that there was a significant reduction in the proportion of Th17 cells in the large 
intestinal lamina propria upon treatment with SGA-360 (Fig. 4B). These results suggest 
that in vivo differentiation of Th17 cells can be inhibited by the inhibition of AHR with 
resultant increase in bacterial burden. 
 
Fig. 4. SGA-360 (partial antagonist) inhibits the differentiation of IL17A expressing 
Th17 cells during CR infection. A) IL17A-GFP reporter mice were infected with 5x109 
CFUs of C. rodentium on day 1 and treated with vehicle control or 20 mg/kg SGA-360 i.p. every 
other day starting from day 0 until the duration of the experiment and the fecal pellets obtained 
at the indicated time points were analyzed for the number of CFUs per gram of feces. B) Single 
cell suspensions of large intestinal lamina propria cells from mice treated as above was 
analyzed for the proportion of CD4+ TCRb+ that express IL-17A-GFP at 10 DPI. Data represents 
Mean±SEM of n≥5 mice, *p<0.05 by 2 way ANOVA (A) and unpaired student t test (B).  
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3.2.4 Activation of AHR affects both the differentiation of Th1 and iTreg cells in 
vivo  
AHR can bind Stat1 and prevent it from binding to IL-17A promoter and hence 
promoting Th17 differentiation [14] . It has also been shown that IFN-the lineage 
defining cytokine of Th1 cells, can negatively regulate the differentiation of Th17 cells 
both in vitro and in vivo [2, 3, 13] . We next wanted to determine if modulation of AHR 
affected IFN-production by CD4+ T cells in vivo in response to C. rodentium. To do 
this, we isolated large intestinal lamina propria cells from day 10 C. rodentium infected 
mice that were either treated with vehicle, -NF or SGA-360. We find that, 
administration of -NF resulted in a significant reduction in the proportion of large 
intestinal lamina propria CD4+ T cells that were able to secrete IFN-but not the IFN-
+IL17A+ double positive cells (Fig. 5A). SGA-360 on the other hand had minimal effect 
both on the differentiation of Th1 cells and the proportion of IFN-+IL-17A+ double 
positive cells (Fig. 5B). Thus addition of -NF promotes Th17 differentiation either 
directly by actively repressing the differentiation of Th1 cells or indirectly by promoting 
Th17 differentiation at the expense of Th1 differentiation. 
Foxp3+ Treg cells play a critical role in immune cell homeostasis by controlling over-
exuberant inflammatory responses. It has been previously shown that, AHR activation 
can promote the differentiation of iTregs in the intestinal mucosa by promoting the 
differentiation of tolerogenic dendritic cells in a retinoic acid dependant manner 
[15].Based on this, we wanted to determine if modulation of AHR with -NF or SGA-360 
affected the differentiation of iTregs in response to C. rodentium. We find that, while 
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SGA-360 had minimal effect, -NF significantly enhanced the proportion of iTregs in the 
large intestinal lamina propria of C. rodentium infected mice (Fig. 5C).  
 
Fig. 5. Activation of AHR affects both the differentiation of Th1 and iTreg cells in 
vivo. (A-C) IL17A-GFP reporter mice were infected with 5x109 CFUs of C. rodentium on day 1 
and treated with vehicle control or 50 mg/kg β-NF or 20 mg/kg SGA-360 i.p. every other day 
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starting from day 0 until the duration of the experiment and single cell suspensions of large 
intestinal lamina propria cells was analyzed for the indicated cell populations at 10 DPI. Data 
represents Mean±SEM of n≥5 mice, *p<0.05 by and unpaired student t test.  
 
3.2.5 Modulation of AHR activity influences the secretion of IL-17A by Innate 
lymphoid cells 
Innate lymphoid cells (ILCs) represent a class of recently identified innate immune cells 
that are developmentally closely related to T helper cells [16]. Group 3 ILCs are a 
subtype of ILCs that are similar to Th17 cells in their transcriptional and cytokine profile. 
Recently it  has been shown that AHR plays an important role in the maintenance of 
steady-state  levels of group 3 ILCs in the intestinal lamina propria [17] [18]. Although 
AHR is critical for the differentiation of Th17 cells, in the absence of AHR there is 
reduced IL-22 that results in increased colonization by the commensal segmented 
filamentous bacteria (SFB), which induces IL-17A secretion by both Th17 cells and ILCs 
[18-21]. Based on this, we wanted to determine how modulation of AHR activity using -
NF or SGA-360 would affect the differentiation of group 3 ILCs that can secrete IL-17A 
in vivo using the C. rodentium infection model. We analyzed the large intestinal lamina 
propria of vehicle, -NF or SGA-360 treated C. rodentium infected mice at 10 DPI for 
the proportion of IL-17A+ ILCs. We find that, activation of AHR with -NF significantly 
increased the percentage of IL-17A+ ILCs while SGA-360 inhibited AHR activity to 
inhibit differentiation of IL-17A+ ILCs (Fig. 6). These results suggest that although at 
steady-state AHR signaling suppresses the differentiation of IL-17A+ ILCs (through the 
AHR-IL-22 axis), inhibition of AHR results in reduced differentiation of IL-17A+ ILCs in 
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response to C. rodentium. Thus targeting AHR is an attractive therapeutic strategy for 
modulation of IL-17A production by both innate and adaptive immune cells in vivo.  
 
Fig. 6. Modulation of AHR activity influences the secretion of IL-17A by Innate 
lymphoid cells. IL17A-GFP reporter mice were infected with 5x109 CFUs of C. rodentium on 
day 1 and treated with vehicle control or 50 mg/kg β-NF or 20 mg/kg SGA-360 i.p. every other 
day starting from day 0 until the duration of the experiment and single cell suspensions of large 
intestinal lamina propria cells was analyzed for the indicated cell populations at 10 DPI. Data 
represents Mean±SEM of n≥5 mice, *p<0.05 by and unpaired student t test. 
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3.2.6 Activation of AHR enhances IL-17A expression by differentiated Th17 cells 
in vivo 
The above results suggest that modulation of AHR activity can differentially regulate 
Th17 differentiation in vivo. Next we wanted to determine if AHR signaling regulates the 
production of IL-17A by fully differentiated Th17 cells. To test this, we used a chronic 
Th17 mediated disease model, hypersensitivity pneumonitis that is induced by the 
gram-positive bacteria S. rectivirgula. Repeated challenge with S. rectivirgula induces 
chronic lung inflammation resulting in extrinsic allergic alveolitis or hypersensitivity 
pneumonitis that is characterized by the collagen deposition and fibrosis in the lungs [9]. 
Th17 cells that are induced in response to S. rectivirgula potentiate inflammation during 
the chronic stages of the disease and hence are pathogenic in this disease model. 
Based on this, we wanted to determine if modulation of AHR activity after disease 
development would influence Th17 responses. To address this, we intra nasally 
challenged IL-17A GFP reporter mice with S. rectivirgula for 3 consecutive weeks (3 
times/week) and subsequently treated the mice intranasally with vehicle or AHR 
modulating compounds for 5 consecutive days on the 3rd week along with S. rectivirgula 
challenge. Administration of -NF during the chronic stages of the disease, after 
induction of Th17 responses against S. rectivirgula, not only increased inflammation 
within the lungs with increased accumulation of CD4+ T cells (Fig. 7A) but it also 
enhanced the production of IL-17A by differentiated Th17 cells (Fig. 7B). These results 
suggest that -NF can enhance the production of IL-17A by fully differentiated Th17 
cells in vivo. 
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IL-17A+  T cells have also been shown to mediate pathology during challenge with S. 
rectivirgula and  T cells express AHR. So we wanted to determine if the proportion of 
IL-17A+ T cells was affected by addition of -NF. Although -NF did not enhance IL-
17A production by  T cells, it promoted increased accumulation of  T cells in the 
lungs (Fig. 7C & 7D). The failure to enhance IL-17A production could be due to intrinsic 
differences in the requirement of AHR signaling by CD4+ T cells versus  T cells or it 
could be secondary to the fact that  T cells have already reached their maximal 
threshold for IL-17A production in response to S. rectivirgula challenge (~70-80% of  
T cells in vehicle treated S. rectivirgula challenged mice can make IL-17A).
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Fig. 7. Activation of AHR enhances IL-17A expression by differentiated Th17 cells 
in vivo. A-D) IL17A-GFP reporter mice were challenged intranasally with S. rectivirgula 
(150mg/ mouse) for 3 consecutive days for 3 weeks followed treatment with either PBS or 0.4 
mg/ mouse β-NF intranasally for 5 consecutive days on the 3rd week. Single cell suspension of 
lungs were stained and analyzed for the indicated cell populations. Data plotted both as 
percentage cells (left panels) and total cell number (right panels). Data represents Mean±SEM 
of n≥5 mice, *p<0.05 by and unpaired student t test.  
 
 
Fig. 7. Activation of AHR enhances IL-17A expression by differentiated Th17 cells 
in vivo. A-D) IL17A-GFP reporter mice were challenged intranasally with S. rectivirgula 
(150mg/ mouse) for 3 consecutive days for 3 weeks followed treatment with either PBS or 0.4 
mg/ mouse β-NF intranasally for 5 consecutive days on the 3rd week. Single cell suspension of 
lungs were stained and analyzed for the indicated cell populations. Data plotted both as 
percentage cells (left panels) and total cell number (right panels). Data represents Mean±SEM 
of n≥5 mice, *p<0.05 by and unpaired student t test.  
PBS -NF0
5
10
15
*
Pe
rc
en
t 
+  
T 
ce
lls
PBS -NF0.0×10
+00
5.0×1004
1.0×1005
1.5×1005
2.0×1005
*
   
N
um
be
r o
f 
+  
T 
ce
lls
PBS -NF0
20
40
60
80
100
   
Pe
rc
en
t 
+ I
L-
17
A
-G
FP
+ 
T 
ce
lls
PBS -NF0.0×10
+00
5.0×1004
1.0×1005
1.5×1005
  
 
N
um
be
r o
f 
+
IL
-1
7A
-G
FP
+ 
T 
ce
lls *
C
D
61 
 
We next wanted to determine if inhibition of AHR activity with the partial antagonist, 
SGA-360 or the complete antagonist GNF can influence production of IL-17A by 
differentiated Th17 cells. Intranasal administration of both SGA-360 and GNF inhibited 
the induction of CYP1a1 transcription in the lungs suggesting that both these 
compounds inhibited AHR activity (Fig. 8A). While addition of SGA-360 and GNF did 
not affect the levels of IL-17A transcripts in the lungs, there was a considerable 
reduction in IL-17F transcripts in both the treatment groups compared to vehicle 
controls (Fig. 8B). Interestingly, both SGA-360 and GNF treatment enhanced the 
expression of IL-4 and IFN-(Fig. 8C) suggesting that these partial and complete 
antagonist compounds can switch the cytokine profile in the lungs of S. rectivirgula 
challenged mice. In line with this, we did not see a significant change in the proportion 
of CD4+ T cells or a reduction in the proportion of Th17 cells in the lungs of compound 
versus vehicle treated S. rectivirgula challenged mice (Fig. 8D) but there was a 
significant increase in the proportion of CD4+ T cells that could make IL-4 (Fig. 8E). We 
did not find an increase in the percentage of IFN-+ CD4+ T cells in the lungs suggesting 
that the increase in IFN- transcripts we observed was not a result of increased 
accumulation of Th1 cells in the lungs (Fig. 8F). Addition of GNF also promoted the 
differentiation Foxp3+ Treg cells in the lungs (Fig. 8G). Taken together, these results 
suggest that although SGA-360 and GNF cannot influence the secretion of IL-17A by 
fully differentiated Th17 cells they could promote anti-inflammatory CD4+ T cell 
responses. It would be interesting to see if this switch in cytokine profile in the SGA-360 
and GNF treatment groups influenced pathophysiology in the chronic stage of the 
disease. 
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Fig. 8. Activation of AHR enhances IL-17A expression by differentiated Th17 cells 
in vivo. C57Bl/6 mice were challenged intranasally with S. rectivirgula (150mg/ mouse) for 3 
consecutive days for 3 weeks followed treatment with either PBS or 0.4 mg/ mouse SGA-360 or 
GNF intranasally for 5 consecutive days on the 3rd week. A-C) qPCR analysis of indicated 
genes in the RNA isolated from lung tissue of mice treated as above, values are normalized to 
GAPDH.  D-G) Single cell suspension of lungs isolated from mice treated as above were 
stained and analyzed for the indicated cell populations. Data plotted both as percentage cells 
except upper right panel which represents total cell number. Data represents Mean±SEM of n≥5 
mice, *p<0.05 by and unpaired student’s t test.  
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Fig. 8. Activation of AHR enhances IL-17A expression by differentiated Th17 cells 
in vivo. C57Bl/6 mice were challenged intranasally with S. rectivirgula (150mg/ mouse) for 3 
consecutive days for 3 weeks followed treatment with either PBS or 0.4 mg/ mouse SGA-360 or 
GNF intranasally for 5 consecutive days on the 3rd week. A-C) qPCR analysis of indicated 
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genes in the RNA isolated from lung tissue of mice treated as above, values are normalized to 
GAPDH.  D-G) Single cell suspension of lungs isolated from mice treated as above were 
stained and analyzed for the indicated cell populations. Data plotted both as percentage cells 
except upper right panel which represents total cell number. Data represents Mean±SEM of n≥5 
mice, *p<0.05 by and unpaired student’s t test.  
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3.3 Discussion 
AHR is expressed in both innate and adaptive immune cells and recently its role in 
modulating Th17/Treg balance in a ligand specific manner has opened up new avenues 
for therapeutics in autoimmune and allergic diseases.  Activation of AHR in CD4+ T cells 
exacerbates EAE by generation of pro-inflammatory Th17 cells in a ligand specific 
manner [22]. However, Th17 cells also have been shown to have protective function, for 
instance in the gut, and hence AHR activation in different disease models can have very 
different outcomes.  In this study we used an intestinal bacterial infection model with C. 
rodentium in which Th17 cells are protective. and also a lung Hypersensitivity 
Pneumonitis model with S. rectivirgula where Th17 cells is pathogenic to assess the 
role of AHR signaling in regulation of Th17 responses in vivo.  
Recently, a novel role of AHR in gut has been elucidated where AHR expression in 
innate immune cells called group 3 innate lymphoid cells (ILCs) are shown to maintain 
gut homeostasis by suppressing pathogenic Th17 cells in steady-state physiological 
conditions [18]. It was shown that AHR  expression in group 3 ILCs regulate the AHR-
IL-22 axis in restricting the aberrant expansion of commensal segmented filamentous 
bacteria (SFB) which increases Th17 population in the gut, thereby negatively 
regulating mucosal Th17 responses [18, 21]. We have shown that systemic activation of 
AHR by an agonist, β-NF during C. rodentium infection increased Th17 responses, 
which resulted in better clearance of bacteria as well as delay of the peak of infection. 
Even though there was an increase of IL-17A from CD3-Thy1.2+ ILCs with β-NF, the 
majority of IL-17A producers were T-cells, and β-NF specifically increased the IL-17A 
expression in large intestinal lamina propria, the site of bacterial infection.  
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It has been shown that IFNγ acts as a negative regulator of Th17 development and here 
we show that β-NF treated mice had less IFNγ producing CD4+T cells, which could be 
one mechanism by which β-NF augments Th17 responses in C. rodentium infected 
mice [2, 3]. Apart from IL-17A, Th17 cells can also co-express IFNγ, which are regarded 
as pathogenic forms of Th17 responses and are responsible for worsening of 
encephalomyelitis, a mouse model of multiple sclerosis [23]. We found that 
administration of β-NF did not affect the CD4+IL-17A+IFNγ+cells, suggesting that AHR 
activation via β-NF specifically enhances CD4+IL-17A+ cells which render a protective 
function through an augmented clearance of C. rodentium. Treatment with partial 
antagonist SGA-360 increased bacterial burden during early stages indicating a 
defective Th17 response due to inactivation of AHR via DRE-driven pathway. IL-17A 
expression was inhibited in SGA-360 vs vehicle treated mice at later time point even 
though there was no appreciable difference in bacterial burden. Since, SGA-360 only 
partly suppresses AHR activation through DRE, it is plausible that AHR activation via 
non-canonical protein-protein interaction may still induce other cytokines like IL-22 
which can aid in bacterial clearance at later time points during C. rodentium infection [5, 
18]. However, it is interesting to note that both β-NF and SGA-360 enhanced or 
suppressed IL-17A in ILCs respectively in large intestinal lamina propria, underscoring 
the specificity of these compounds to modulate Th17 response to C. rodentium. 
It has been shown that fully differentiated Th17 cells generated in vivo retain AHR 
expression and hence it is conceivable that modulation of AHR activity in these cells 
can affect IL-17A production [24] . Similar to the acute C. rodentium infection model, in 
a chronic model of Th17 mediated disease, hypersensitivity pneumonitis induced by S. 
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rectivergula, -NF enhanced Th17 responses. However, while the AHR antagonists 
SGA-360 and GNF had minimal effect on already established Th17 responses, they 
were able to enhance IL-4 production by CD4+ T cells. In addition to this GNF promoted 
differentiation of Treg cells. Thus while activation of AHR in fully differentiated Th17 
cells can further enhance IL-17A production, inhibition of AHR activity does not 
influence IL-17A production but can promote an anti-inflammatory environment. Fate 
mapping studies have shown that under chronic inflammatory settings like EAE, Th17 
cells are more plastic and can be induced to secrete other cytokines to adopt alternate 
fates [24]. Also, it has been shown that AHR can affect both Th17 and Treg 
differentiation in a ligand specific manner [15, 22, 25] .Hence, it would be interesting to 
see if the CD4+ T cells that were induced make IL-4 or express Foxp3 upon addition of 
AHR antagonists were IL-17A secreting Th17 cells prior to addition of the compounds. If 
true, this would imply that modulation of AHR could alter Th17 cell plasticity in vivo and 
hence offers attractive therapeutic opportunities for chronic inflammatory diseases. 
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3.4 Materials and Method 
3.4.1 Mice and treatments. C57bl/6 and IL17A-GFP reporter mice were purchased from 
Jackson laboratories and Biocytogen respectively. All mice were used between 6- and 12-
wk of age and maintained in a specific pathogen free environment.  
For C. rodentium infection, Citrobacter rodentium strain ICC 169 the Nalidixic Acid 
resistant strain was cultured in LB with nalidixic acid at 50µg/ml over night and then mice 
were gavaged with 5x109 CFUs (calculated based on OD) of C. rodentium. Bacterial 
shedding was calculated using the following formula 
(Average # colonies (CFU) / 0.025 ml (volume plated))  x  dilution factor  = CFU/ml 
Then factor in the initial addition of PBS to feces for homogenization 
CFU / ml x 1 ml PBS / 0.1 g feces = CFU/ g feces                                       
For hypersentivity pneumonitis experiments B6 mice were given 150μg (50μl) of S. 
rectivirgula (American Type Tissue Collection catalogue no. 29034) or sterile 1X PBS. 
Mice were lightly anesthetized with isoflurane and either S.rectivirgula or sterile PBS. was 
administered intranasally for 3 consecutive days for 3 weeks. S. rectivirgula was prepared 
by growing the microorganism in tryptic soy broth at 55°C with constant agitation. The S. 
rectivirgula culture was centrifuged, resuspended in sterile PBS, and the concentration of 
the SR protein was quantified by Thermo Scientific Pierce BCA Protein Assay Kit 
(Thermo Fisher Inc). All experiments were approved by the Office of Research 
Protection’s Institutional Animal Care and Use Committee at Pennsylvania State 
University and by the National Institutes of Health. All experiments were performed in 
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accordance with the regulations of the Office of Research Protection’s Institutional Animal 
Care and Use Committee at Cornell University and the National Institutes of Health. 
 
3.4.2 Quantitative PCR. RNA was extracted either using TRIZOL reagent (Invitrogen) or 
using the RNAeasy kit (Invitrogen) and cDNA was generated with a kit from You Prime 
First-Strand beads kit (GE Biosciences). q-PCR was then performed with all values 
normalized to respective GAPDH values and the data expressed as 2-DDCt (where Ct is 
threshold cycle), the values are represented as fold change over respective controls. 
 
3.4.3 Flow cytometry and analysis of cytokines and transcription factors. Where 
indicated cells were stimulated with PMA/Ionomycin (Sigma) in the presence of Brefeldin 
A (Sigma) for 5 hours. Stimulated or unstimulated cells were fixed with Foxp3 fixation/ 
permeabilization kit (eBioscience) was used to fix/ permeabilize cells and then stained for 
the indicated surface proteins, and intracellular proteins. LSRII flow cytometer (BD 
Biosciences) was used to acquire data and the data was analyzed with FlowJo 
(TreeStar). 
  
3.4.4 Data analysis. Statistical analysis was done with Student’s t test, linear regression 
analysis, two-way ANOVA using GraphPad Prism version 5.00 for Windows (GraphPad, 
San Diego, CA).  Differences with probability p ≤ 0.05 were considered statistically 
significant. 
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CHAPTER 4 
 
 
CD8+ T cells modulate the progression of 
Hypersensitivity Pneumonitis by regulating IL-17A 
expression in the lungs 
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4.1 Introduction 
Hypersensitivity pneumonitis (also called extrinsic allergic alveolitis, EAA) is an 
inflammation of the alveoli within the lung caused by hypersensitivity to aerosolized 
antigen [1, 2]. HP is an environmental disease caused by repeated exposure to 
aerosolized antigens. In humans an example of HP, also called ‘Farmer’s lung,’ is 
caused by thermophilic bacteria called Saccharopolyspora rectivergula (S.rectivirgula) 
due to repeated exposure to moldy hay [1-5].  HP occurs in three clinical forms acute, 
sub-acute and chronic with chronic patients suffering from pulmonary fibrosis and 
irreversible pulmonary dysfunction. In mice exposed to SR, the disease is characterized 
by lung fibrosis and mononuclear infiltrates mostly composed of macrophages and T 
cells [2, 6-8]. Recently it has been shown that peribronchovascular mononuclear 
infiltrates and resultant pulmonary fibrosis due to SR is caused by Th17 cells and IL-
17A production [2]. CD8+ T cells on the other hand have been shown to play a role in 
promoting inflammation during the acute stages of the disease [4, 9]. During acute 
inflammation, CD8+ T cells interact with activated alveolar macrophages and secrete 
inflammatory mediators like IL-12, IL-2, IL-8 and IL-16. In humans, CD8+ T cells have 
been shown to promote fibrosis and worsening of pulmonary function parameters with 
increased number of CD8+ T cells correlating with exacerbated disease. Here, cytokines 
and chemokines produced by CD8+ T cells directly and indirectly (through recruitment of 
other immune cells) increase collagen deposition and fibrosis. Also, like naïve CD4+ T 
cells, naïve CD8+ T cells have been shown to secrete IL-17A when cultured in the 
presence of TGF- and IL-6 [10].  However, CD8+ T cells may have minimal role in the 
development of pulmonary fibrosis in the chronic stages of S. rectivirgula mediated 
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hypersensitivity pneumonitis in mice as adoptive transfer of CD8+ T cells into TCR-/--/- 
hosts followed by S. rectivirgula treatment resulted in minimal accumulation of CD8+ T 
cells in the lungs and reduced collagen deposition compared to hosts that received 
CD4+ T cells[2]. While, this suggests that CD8+ T cells may not directly regulate 
pathology during chronic stages of hypersensitivity pneumonitis, whether CD8+ T cells 
interact with other immune cell subsets to influence disease pathophysiology has not 
been investigated. Here we show that, depletion of CD8+ T cell post induction of 
hypersensitivity pneumonitis did not affect the recruitment and/or maintenance of CD4+ 
T cells in the lungs and bronchoalveolar regions but enhanced Th17 responses in both 
resulting in increased mononuclear infiltrates in the lungs. In line with this, CD8-/- mice 
show increased susceptibility to S. rectivirgula challenge with mice succumbing to 
disease as early as 2 weeks post S. rectivirgula challenge. These results suggest that 
CD8+ T cells negatively regulate Th17 responses control against excessive 
inflammation against S. rectivirgula. 
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4.2 Results 
4.2.1 Depletion of CD8+ T cells during chronic hypersensitivity pneumonitis does 
not affect the accumulation of CD4+ T cells in the lungs 
CD4+ T cells are the major contributor of lung pathology in hypersensitivity pneumonitis, 
and the number of CD4+ T cells positively correlates with increased disease severity. 
Since the role of CD8+ T cells in acute inflammation has been well established, we 
wanted to determine if CD8+ T cells influence disease outcome during the chronic 
stages. To do this, we challenged mice with S. rectivirgula for 3 weeks (3 consecutive 
days per week) and depleted CD8+ T cells after the induction of hypersensitivity 
pneumonitis (Fig. 1). Administration of -CD8 antibody resulted in a significant 
reduction in the percentage and number of CD8+ T cells in the lungs (Fig. 2A) as well 
as in the spleen and lymph nodes (Fig. 2B). Depletion of CD8+ T cells had no effect on 
the accumulation of CD4+ T cells in the lungs of S. rectivirgula challenged CD8 depleted 
versus non depleted mice (Fig. 2C). Similarly depletion of CD8+ T cells had minimal 
effect on the accumulation of CD4+ T cells in the bronchoalveolar lavage (Fig. 2D). This 
suggests that, CD8+ T cells have no effect on the maintenance and/or recruitment of 
CD4+ T cells during hypersensitivity pneumonitis. 
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Fig.1 Schematic of S. rectivirgula challenge. Model diagram depicting the experimental 
layout for S. rectivirgula and CD8 depletion.  
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Fig.2 Depletion of CD8+ T cells during chronic hypersensitivity pneumonitis does 
not affect the accumulation of CD4+ T cells in the lungs. C57Bl/6 mice were 
intranasally exposed with S. rectivirgula (150μg/mouse) and injected either with PBS or an 
antibody against CD8 (200 μg/mouse i.p.). Single cell suspensions obtained from lungs (A) and 
spleen/ lymph node (B) were stained for CD8+ T cells and analyzed by Flow cytometry. Single 
cell suspensions obtained from lungs (C) and BALF (D) of mice treated as above were analyzed 
for the percentage of infiltrating CD4+ T cells by flow cytometry. Data represents Mean±SEM of 
n≥5 mice, *p<0.05 by unpaired students t test.  
 
4.2.2 Depletion of CD8+ T cells, post hypersensitivity pneumonitis induction, 
results in increased expression of IL-17A and IL-17F transcripts in the lungs. 
In line with published results, challenge with S. rectivirgula resulted in a strong induction 
of IL-17A transcripts within the lungs (Fig. 3A). Interestingly, depletion of CD8+ T cells 
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following the induction of chronic inflammation further increased the level of IL-17A 
within the lungs (Fig. 3B). Depletion of CD8+ T cells also resulted in an increase in the 
levels of IL-17F, a cytokine that is functionally similar but less potent as compared to IL-
17A (Fig. 3C). Depletion of CD8+ T cells during the chronic stage, had minimal effect on 
the level of IFN- transcripts (Fig. 3D), another cytokine that has been shown to play a 
role in disease pathology during hypersensitivity pneumonitis. These results suggest 
that depletion of CD8+ T cells can promote IL-17A mediated inflammation in the airways 
upon S. rectivirgula challenge. 
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Fig.3 Depletion of CD8+ T cells, post hypersensitivity pneumonitis induction, 
results in increased expression of IL-17A and IL-17F transcripts in the lungs. A) 
C57Bl/6 mice were intranasally exposed with S. rectivirgula (150μg/mouse) or PBS and RNA 
isolated from total lung tissue analyzed for the expression of IL-17A by qPCR. B-D) S. 
rectivirgula  challenged mice were injected either with PBS or an antibody against CD8 (200 
μg/mouse i.p.). QPCR analysis of RNA isolated from total lung tissue was analyzed for IL-17A, 
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IL-17F and IFNγ genes. Data represents Mean±SEM of n≥5 mice, *p<0.05 by unpaired students 
t test. 
 
4.2.3 Depletion of CD8+ T cells, post hypersensitivity pneumonitis induction, 
results in increased number of pathogenic Th17 cells in the lungs. 
Th17 polarized CD4+ T cells have been shown to play an important role in the 
development of inflammation and pulmonary fibrosis in S. rectivirgula challenged mice. 
Since we observed an increase in the levels of IL-17A and IL-17F transcripts in the 
lungs of S. rectivirgula challenged mice upon depletion of CD8+ T cells, we wanted to 
determine if the loss of CD8+ T cells had any effect on number of IL-17A producing 
CD4+ T cells. We find that in the absence of CD8+ T cells there was increased 
accumulation of IL-17A producing CD4+ T cells both in the lungs (Fig. 4A) and in the 
bronchoalveolar lavage (Fig. 4B). Depletion of CD8+ T cells neither affected the number 
of Treg cells nor the number of IL-10 producing CD4+ T cells (Fig. 4C), suggesting that 
CD8+ T cells regulated Th17 responses independent of regulatory CD4+ T cells.  In line 
with the fact that, we did not see a difference in IFN- transcript levels, depletion of 
CD8+ T cells did not affect the number of IFN-+ CD4+ T cells in the lungs (Fig. 4D) and 
in the bronchoalveolar lavage (Fig. 4E). These results suggest that, CD8+ T cells 
negatively regulate Th17 responses during the chronic stages of hypersensitivity 
pneumonitis. 
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Fig.4 Depletion of CD8+ T cells, post hypersensitivity pneumonitis induction, 
results in increased number of pathogenic Th17 cells in the lungs. C57Bl/6 mice 
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were treated with S. rectivirgula (150μg/mouse) and injected either with PBS or an antibody 
against CD8 (200 μg/mouse i.p.). Single cell suspensions obtained from lungs (A) and BALF (B) 
were stimulated with PMA and Ionomycin in the presence of Brefeldin A and analyzed for the 
percentage of IL-17A+ producing CD4 T cells. C) Single cell suspensions obtained from lungs of 
mice treated as above were analyzed for the percentage of CD4+ Foxp3+ T cells and CD4+ IL10+ 
cells. D&E) Single cell suspensions obtained from lungs (D) and BALF (E) of mice treated as 
above were stimulated with PMA and Ionomycin in the presence of Brefeldin A and analyzed for 
the percentage of IFN-g+ producing CD4 T cells. Data represents Mean±SEM of n≥5 mice, 
*p<0.05 by unpaired students t test.  
 
4.2.4 Absence of CD8+ T cells exacerbates inflammation in the lungs during 
hypersensitivity pneumonitis 
Consistent with our findings that there were more Th17 cells in the lungs in the absence 
of CD8+ T cells, H&E staining of lung sections from CD8+ T cell depleted mice revealed 
increased number of peribronchovascular mononuclear infiltrates. Also, there was 
higher bronchiolar lumen occlusion in the CD8+ T cell depleted mice compared to non-
depleted controls (Fig. 5A).To further confirm the role of CD8+ T cells in the regulation 
of hypersensitivity pneumonitis, we challenged CD8-/- mice with S. rectivirgula and found 
that these mice exhibit an exacerbated pathophysiology as shown by the fact that there 
was increased mononuclear infiltrates in the lungs (Fig. 5B). S. rectivirgula CD8-/- mice 
were also increasingly susceptible with mice succumbing to disease as early as 2 
weeks post challenge (data not shown), which suggest that CD8+ T cells are important 
for survival and an optimal immune response to S. rectivirgula. To date, Th17 polarized 
CD4+ T cells have been shown to be the major contributor of hypersensitivity 
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pneumonitis, here we show that CD8+ T cells play an important role in regulating the 
severity of the disease.  
 
 
Fig. 5. Absence of CD8+ T cells exacerbates inflammation in the lungs during 
hypersensitivity pneumonitis. A) C57Bl/6 mice were treated with S. rectivirgula  
(150μg/mouse) and injected either with PBS or an antibody against CD8 (200 μg/mouse i.p 
Lung sections were stained for H & E and analyzed at a magnification of 2.5x. B) C57Bl/6 or 
CD8-/- mice were treated with S. rectivirgula  (150μg/mouse) and lung sections were stained for 
H & E and analyzed at a magnification of 20x. 
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Fig. 5. Absence of CD8+ T cells exacerbates inflammation in the lungs during 
hypersensitivity pneumonitis. A) C57Bl/6 mice were treated with S. rectivirgula  
(150μg/mouse) and injected either with PBS or an antibody against CD8 (200 μg/mouse i.p 
Lung sections were stained for H & E and analyzed at a magnification of 2.5x. B) C57Bl/6 or 
CD8-/- mice were treated with S. rectivirgula  (150μg/mouse) and lung sections were stained for 
H & E and analyzed at a magnification of 20x. 
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4.3 Discussion 
Hypersensitivity pneumonitis is a chronic inflammatory disease that is mediated by 
repeated exposure to certain environmental antigens and can result in collagen 
deposition leading to fibrosis in the lungs [11]. Antigens from the thermophile S. 
rectivirgula are one such class of environmental antigens that can cause 
hypersensitivity pneumonitis upon repeated exposure both in humans and mice [1, 3, 5, 
12]. Inflammation in the chronic stages of S. rectivirgula mediated hypersensitivity 
pneumonitis is mainly driven by IL-17A producing CD4+ T cells, as there is significantly 
lower inflammation and lung fibrosis both in the absence of  T cells or in the absence 
of IL-17A receptor signaling [2]. Although, CD8+ T cells play a role during the acute 
stages of the disease [4, 9], adoptive transfer experiments have suggested that CD8+ T 
cells play minimal role in the pathogenesis when transferred by themselves during the 
chronic stages of hypersensitivity pnenumonitis [2]. However, whether CD8+ T cells 
promote or control responses of other immune cell subsets to S. rectivirgula has not 
been investigated. In the absence of CD8+ T cells during the chronic stages of 
hypersensitivity pneumonitis there is a marked increase in the infiltration and/ or 
expansion of Th17 cells, which resulted in an increase in mononuclear infiltrates within 
the lungs. Also, upon chronic exposure to S. rectivirgula CD8-/- mice had increased 
mononuclear infiltrates and pathology in the lungs. These results underscore a 
previously unappreciated role for CD8+ T cells in the regulation of Th17 responses in 
the lungs. 
Recently it has been shown that under chronic inflammatory settings such as EAE, IL-
17A producing CD8+ T cells can promote Th17 responses. Importantly this help 
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provided by CD8+ T cell in enhancing CD4+ T cell responses were contingent upon 
secretion of IL-17A by CD8+ T cells and is mediated by a cell-cell interaction between 
CD8+ and CD4+ T cells [10]. This is supported by the fact that, CD8-/- mice have lower 
disease pathology during EAE and depletion of CD8+ T cells with neutralizing CD8 
antibody resulted in less severe disease [10, 13]. This promotion of Th17 responses by 
CD8+ T cell was further enhanced under lymphopenic environment [10]. Although these 
results provide a strong evidence for enhancement of Th17 responses by IL-17A+ CD8+ 
T cells, it is not clear if this holds true for other subsets of CD8+ T cells and/ or during 
different chronic inflammatory settings. Our results, suggest that control of CD4+ T cell 
responses by CD8+ T cells is much more complex and is dependent on the 
inflammatory setting. As in the case of the chronic inflammatory disease hypersentivity 
pneumonitis, where there is very minimal to no induction of IL-17A+ CD8+ T cells (data 
not shown), absence of CD8+ T cells resulted in a more exaggerated Th17 response 
resulting in  more severe pathology. This to our knowledge is the first report suggesting 
that under certain chronic inflammatory settings CD8+ T cells can inhibit Th17 
responses to curb excessive inflammation. It would be interesting to see if this control of 
CD4+ T cell response is dependent on cell-cell interaction and what are the other factors 
that govern CD8+ T cell mediated control versus promotion of Th17 response.  
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4.4 Materials and Methods 
4.4.1 Mice and treatments. C57bl/6 mice were purchased from Jackson laboratories. All 
mice were used between 6- and 12-wk of age and maintained in a specific pathogen free 
environment. For hypersentivity pneumonitis experiments B6 mice were given 150μg 
(50μl) of S. rectivirgula (American Type Tissue Collection catalogue no. 29034) or sterile 
1X PBS. Mice were lightly anesthetized with isoflurane and either S.rectivirgula or sterile 
PBS was administered intranasally for 3 consecutive days for 3 weeks. S. rectivirgula was 
prepared by growing the microorganism in tryptic soy broth at 55°C with constant 
agitation. The S. rectivirgula culture was centrifuged, resuspended in sterile PBS, and the 
concentration of the SR protein was quantified by Thermo Scientific Pierce BCA Protein 
Assay Kit (Thermo Fisher Inc). All experiments were approved by the Office of Research 
Protection’s Institutional Animal Care and Use Committee at Pennsylvania State 
University and by the National Institutes of Health. All experiments were performed in 
accordance with the regulations of the Office of Research Protection’s Institutional Animal 
Care and Use Committee at Cornell University and the National Institutes of Health. 
 
4.4.2 Quantitative PCR. RNA was extracted either using TRIZOL reagent (Invitrogen) or 
using the RNAeasy kit (Invitrogen) and cDNA was generated with a kit from You Prime 
First-Strand beads kit (GE Biosciences). q-PCR was then performed with all values 
normalized to respective GAPDH values and the data expressed as 2-DDCt (where Ct is 
threshold cycle), the values are represented as fold change over respective controls. 
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4.4.3 Flow cytometry and analysis of cytokines and transcription factors. Where 
indicated cells were stimulated with PMA/Ionomycin (Sigma) in the presence of Brefeldin 
A (Sigma) for 5 hours. Stimulated or unstimulated cells were fixed with Foxp3 fixation/ 
permeabilization kit (eBioscience) was used to fix/ permeabilize cells and then stained for 
the indicated surface proteins, and intracellular proteins. LSRII flow cytometer (BD 
Biosciences) was used to acquire data and the data was analyzed with FlowJo 
(TreeStar). 
4.4.4 Data analysis. Statistical analysis was done with Student’s t test using GraphPad Prism 
version 5.00 for Windows (GraphPad, San Diego, CA).  Differences with probability p ≤ 0.05 were 
considered statistically significant 
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5.1 Summary 
 
Subsets of CD4+ T cells (Th1, Th2, Th17 and Treg) play a vital role in adaptive immune 
responses, regulating both inflammatory and anti-inflammatory processes, providing 
both immune protection as well as mediating immune pathology. Modulation of AHR 
signaling has been shown to regulate differentiation of all these four T helper cell 
subsets, but recently much emphasis has been placed on its role in regulation of Th17 
and Treg responses as AHR is believed to be a potential link in the observed interplay 
between environmental stress and autoimmune diseases [1-6]. Th17 cells are a subset 
of CD4+ T cells that are required for clearance of extracellular pathogens and fungi and 
have been implicated in the development of a number of chronic immune-mediated 
diseases [7-9]. Th17 cells secrete IL-17A and IL-17F among six other IL-17 family 
cytokines and can coordinate with innate immune cells like neutrophils, inducing their 
recruitment to the site of inflammation for an integrated and optimal immune response 
[8, 10, 11]. Treg cells on the other hand are another subset of CD4+ T cells that play a 
balancing role in controlling aberrant immune responses that includes control against 
autoimmune and inflammatory pathologies [11, 12]. Thus, the regulation of Th17/Treg 
axis is critical for the control of inflammatory and autoimmune diseases [2, 3, 8, 13]. 
Aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor, which acts as 
an environmental sensor that can bind to ligands like polycyclic aromatic compounds 
(for example environmental pollutants and industrial byproducts)  to induce toxic 
responses mediated by xenobiotic enzymes [6, 14, 15]. In addition, recent evidence 
points towards AHR signaling to play a critical role in regulation of both the innate and 
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adaptive immune responses [4, 15-20]. Along these lines, AHR signaling has been 
shown to regulate IL-17A and IL-22 secretion by innate lymphoid cells, agonists of AHR 
have been shown to induce tolerogenic DCs and also AHR has been identified as one 
of the factors that can regulate both Th17 and Treg cell differentiation [2, 3, 21-23]. 
Control of Th17/Treg cell axis by AHR is especially interesting, as it seems to do this in 
a ligand specific manner. TCDD or dioxin, the most potent AHR agonist, suppresses 
EAE by promoting differentiation of Treg cells while FICZ, also an agonist of AHR 
exacerbates EAE by promoting differentiation of Th17 cells, suggesting ligand 
dependent functions of AHR in controlling the Th17/Treg axis [2, 3, 24]. This 
phenomenon of ligand specific activation of AHR resulting in very different functional 
outcomes, can at least partly be explained by the fact that AHR can be activated by 
either the binding of ligand-AHR complex to its cognate response elements, dioxin 
response element (DRE) or through a DRE independent pathway. In this study, we 
have used three classes of AHR ligands, agonist of AHR (β-NF, TCDD and FICZ) that 
activates both the DRE- and non-DRE driven pathways, AHR antagonist (GNF) that 
inhibits both the DRE- and non-DRE and a selective AHR modulator (SGA-360), a 
partial antagonist, which would selectively activate the non-DRE driven responses 
without the induction of the DRE-mediated pathway. The study of SAHRMs for example, 
SGA-360 are interesting as they are useful tools to understand the differential role of 
DRE versus non-DRE driven responses in modulating Th17/Treg axis. 
Here we show that, AHR can regulate IL-17A secretion by activated CD4+ T cells under 
non-polarizing conditions. Under these conditions while agonists of AHR promoted IL-
17A production, a partial antagonist inhibited it, suggesting that selective inhibition of 
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the DRE mediated pathway was sufficient to inhibit IL-17A both at the level of 
transcription and translation. Similarly, we find that regulation of Th17 differentiation is 
mediated by a DRE-mediated pathway, as both SGA-360 and GNF can efficiently inhibit 
differentiation of naïve CD4+ T cells into Th17 cells. AHR has been shown to interact 
with Stat3 to regulate the expression of Aiolos, which can silence Il2 locus to promote 
Th17 differentiation [25]. Also, IFNγ mediated activation of Stat1 can inhibit both TH17 
and Treg differentiation. It has been shown that AHR is capable of interacting with Stat1 
and Stat5 at least under Th17 polarizing conditions, preventing them from binding to the 
Il17a promoter and hence promoting IL-17A expression [26]. Based on this, it would be 
interesting to evaluate if inhibition of the DRE-mediated AHR pathway affects the 
interaction between these Stat proteins and AHR. Interestingly, suppression of Foxp3 
expression during Th17 differentiation was mediated by a DRE-independent mechanism 
as only the complete antagonist GNF could reduce the expression of Foxp3 under these 
conditions. On the other hand, selective activation of the non-DRE mediated pathway by 
SGA-360 under Treg skewing conditions did not repress Foxp3 expression, but 
activation of the DRE- driven pathway was required to further enhance Foxp3 
expression albeit in a ligand specific manner (TCDD and FICZ but not β-NF). GNF 
which blocks both the DRE and non-DRE driven pathways, significantly reduced the 
differentiation of naïve CD4+ T cells into Tregs. It has been shown that upon activation 
by TCDD, AHR can directly bind to both the conserved AHR binding sites (CABS) and 
the non-evolutionarily conserved AHR binding sites (NCABS) in the Foxp3 locus to 
regulate its expression [2]. The ability of the above mentioned ligands of AHR to 
activate or inhibit binding of AHR to these regions could dictate whether they promote or 
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inhibit Treg differentiation. Along these lines, it is imperative to study SAHRMs that can 
selectively activate the DRE response while inhibiting the non-DRE driven pathway, to 
further delineate the role of DRE versus non-DRE pathways in the regulation of Foxp3 
expression. These results significantly adds to our current understanding of the role of 
AHR signaling in regulation of Th17 versus Treg cell differentiation as we provide a 
basis for the observed ligand specific function of AHR, differential activation of DRE 
versus non-DRE mediated pathways by ligands. Furthermore, it would be interesting to 
see if AHR signaling regulates signaling pathways that are known to differentially 
regulate effector versus regulatory CD4+ T cell differentiation like the mTORC signaling 
pathway [27]. 
These results highlight the importance of AHR signaling in control of Th17/ Treg 
differentiation and underscore the complexity in AHR’s regulation of these signaling 
events. The fact that AHR can also regulate the secretion of IL-22 by CD4+ T cells, 
production of both IL-17A and IL-22 by innate lymphoid cells and promote differentiation 
of tolerogenic DC’s in vivo, further adds to this complexity  [28-33]. This is most 
apparent in the gut, where in spite of the fact that AHR has been shown to be a critical 
transcription factor for differentiation of Th17 cells, absence of AHR, as in the case of 
AHR-/- mice, promotes intestinal Th17 responses [2, 34]. This is in stark contrast to what 
is known about AHR signaling in pathogenesis during EAE, where the absence of AHR 
ameliorates disease progression [3]. Also, inhibition of the enzyme kynurenine 3-
monooxygenase (KMO), which catabolizes endogenous ligands of AHR has been 
shown to promote Th17 responses to exacerbate autoimmune gastritis [35]. In addition 
to this, Th17 cell plasticity, which is defined by its ability to produce alternate Th lineage 
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cytokines, varies between acute and chronic inflammatory conditions [36].  Thus it is 
important to better understand how activation and inhibition of AHR signaling with AHR 
ligands would influence Th cell responses in vivo for further validation of AHR as a 
therapeutic target. 
 
Using the acute C. rodentium mediated infection model (where Th17 is protective) and 
the chronic S. rectivirgula mediated hypersensitivity pneumonitis model (where Th17 is 
pathogenic) we show that activation of AHR by the agonist β-NF can promote both Th17 
differentiation (C. rodentium model) and enhance IL-17A by fully differentiated Th17 
cells (S. rectivirgula model). Inhibition of AHR on the other hand can inhibit Th17 
differentiation but has minimal effect on the ability of fully differentiated Th17 cells to 
make IL-17A. It is interesting to note that in the chronic S. rectivirgula model, even 
though both the partial and complete antagonist has no effect on the IL-17A production, 
there was significant promotion of anti-inflammatory responses by increase in IL-4 (both 
in GNF and SGA-360) and an increase in the expression of Foxp3 (GNF) (Fig1 & 2).  
This work has implications for understanding AHR as a therapeutic target for both acute 
and chronic inflammatory diseases in the context of regulation of pro- versus anti-
inflammatory responses including effector versus regulatory T helper cell differentiation. 
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Fig.1. Effect of DRE- mediated activation on Th17 differentiation 
Agonists (FICZ, β-NF, TCDD) of AHR can activate both the DRE and NON-DRE driven 
responses to promote Th17 differentiation from naïve CD4+ T cells and on already differentiated 
Th17 cells it can further enhance Th17 differentiation. 
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Fig. 2. Effect of DRE-mediated inhibition on Th17 differentiation 
Both antagonists (GNF) and partial antagonist (SGA-360) can inhibit DRE driven responses and 
can suppress Th17 differentiation from naïve CD4+ T cells and on already differentiated Th17 
cells have minimal effect but can produce alternate lineage cytokines. 
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